Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

The board (the "**Board**") of directors (the "**Directors**") of Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司) (the "**Company**" or "**Asymchem**", and together with its subsidiaries, the "**Group**") is pleased to announce the audited consolidated annual results of the Group for the year ended 31 December 2025 (the "**Reporting Period**"), together with the comparative figures for the year ended 31 December 2024 (the "**Corresponding Period**"). The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Board and the Audit Committee and audited by the Company's auditors.

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places, as appropriate. Any discrepancies in any table, chart, or elsewhere between totals and sums of amounts listed therein are due to rounding. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as ascribed thereto in the prospectus of the Company dated 30 November 2021 (the "**Prospectus**").

In this announcement, unless otherwise indicated, the terms "affiliate", "associate", "associated corporation", "connected person", "controlling shareholder", "subsidiary" and "substantial Shareholder" shall have the meanings given to such terms in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Hong Kong Stock Exchange**") (the "**Hong Kong Listing Rules**").

This announcement is prepared in English. In case of any divergence of interpretations, the English version shall prevail.

FINANCIAL HIGHLIGHTS

Revenue for the year ended 31 December 2025 (the **"Reporting Period"**) was approximately RMB6,670,181 thousand, representing an increase of 14.91% from approximately RMB5,804,657 thousand for the Corresponding Period.

Gross profit margin for the Reporting Period was approximately 41.59%, representing an increase of 0.56 percentage points from 41.03% for the Corresponding Period.

Net profit attributable to shareholders of the listed company for the Reporting Period amounted to approximately RMB1,132,570 thousand, representing an increase of 19.35% from approximately RMB948,950 thousand for the Corresponding Period.

Non-IFRS adjusted net profit attributable to shareholders of the listed company for the Reporting Period amounted to approximately RMB1,253,488 thousand, representing an increase of 56.09% from approximately RMB803,069 thousand for the Corresponding Period.

The Board proposed the 2025 profit distribution plan of the Company (the **"2025 Profit Distribution Plan**") as follows: a dividend of RMB13.00 (tax inclusive) per 10 ordinary Shares for the year ended 31 December 2025, with the total amount of the proposed final dividend amounting to approximately RMB467,640,771.00 (tax inclusive). The proposed 2025 Profit Distribution Plan is subject to the approval of the Shareholders at the AGM.

	For the year ended 31 December		
	2025	2024	Change
	***RMB'000* (except percentages)**		*%*
Results of Operations:			
Revenue	**6,670,181**	5,804,657	14.91
Gross profit	**2,773,796**	2,381,710	16.46
Profit for the year	**1,126,642**	935,756	20.40
Net profit attributable to shareholders of the listed company	**1,132,570**	948,950	19.35
Profitability:			
Gross profit margin	**41.59%**	41.03%	0.56
Net profit margin attributable to shareholders of the listed company	**16.98%**	16.35%	0.63
Non-IFRS Measures:			
Adjusted net profit attributable to shareholders of the listed company	**1,253,488**	803,069	56.09
Adjusted net profit margin attributable to shareholders of the listed company	**18.79%**	13.83%	4.96
Earnings per share (RMB):			
– Basic	**3.16**	2.69	17.66
– Diluted	**3.16**	2.69	17.66

	For the year ended 31 December		
	2025	2024	Change
	***RMB'000* (except percentages)**		*%*
Total assets	**20,277,466**	19,288,556	5.13
Total liabilities	**2,631,326**	2,425,984	8.46
Total equity	**17,646,140**	16,862,572	4.65
Equity attributable to owners of the listed company	**17,635,099**	16,845,384	4.69
Cash and bank balances	**6,320,950**	5,789,408	9.18
Gearing ratio *(Note 2)*	**12.98%**	12.58%	0.40

Note 1: Please refer to "Management Discussion and Analysis – II. Financial Review – (xxiv) Adjusted Non-IFRS Measures".

Note 2: Gearing ratio is calculated by dividing total liabilities by total assets.

MANAGEMENT DISCUSSION AND ANALYSIS

I. BUSINESS REVIEW

In 2025, the Company comprehensively advanced business growth by remaining committed to its business principle of "deepening cooperation with major clients, expanding into small and medium-sized customer segments, advancing market presence in Europe, and enhancing cost efficiency and effectiveness." This involved upgrading the management and operational systems to ensure order delivery capabilities, reinforcing relationships with key clients, and actively pursuing growth opportunities in both domestic and international markets. By leveraging iterative technological advancements, we successfully promoted the advantages of small molecule drug CDMO services, expanded into chemical macromolecule CDMO, biological macromolecule CDMO, drug product services, clinical research services, and synthetic biology technology and export of new technologies. Amid the recovery of the pharmaceutical industry from its downturn and supported by positive signals reflected in changing pharmaceutical industry trends, the Company continued its market expansion, particularly in growth business segments such as peptides, oligonucleotides and antibody-drug conjugates ("**ADCs**"), laying a robust foundation for sustained and steady growth in future performance. In the face of uncertainties in global trade and policy, the Company will leverage its Sandwich site to further advance the development of overseas commercial manufacturing capacity, while balancing the implementation of its global expansion strategy with effective cost control. As at the date of this announcement, excluding orders for which revenue was recognized during the Reporting Period, the Company has secured a total order backlog of US$1,385 million, rising by 31.65%. The rapid order growth of the chemical macromolecule CDMO business and biological macromolecule CDMO business laid a solid foundation for further accelerated growth in future performance.

During the Reporting Period, the Company achieved a total revenue of RMB6,670 million, with an increase of 14.91% year-on-year and an increase of 16.78% at a constant exchange rate. In the fourth quarter, revenue reached RMB2,040 million, marking a quarter-on-quarter increase of 41.53%, a year-on-year increase of 22.59% and a year-on-year increase of 30.84% at a constant exchange rate. As the effects of cost reduction and efficiency improvement measures became apparent, along with the increasing delivery scale of emerging businesses and the ramp-up of capacity utilization, the Company recorded a net profit attributable to shareholders of the listed company of RMB1,133 million, marking a 19.35% rise year-on-year. The adjusted net profit attributable to shareholders of the listed company amounted to RMB1,253 million, growing by 56.09% year-on-year.

Market Expansion and Diversified Customer Base

The Company accelerated global expansion and continued to grow its customer base. In 2025, the Company expanded its CDMO customer base by over 300.

Adhering to the principle of "deepening cooperation with major clients", the Company gradually extended its service chain. During the Reporting Period, revenue from big pharmaceutical ("**Big Pharma**") companies was RMB2,916 million, representing an 8.36% increase compared to the same period last year. Upholding "expanding into small and medium-sized customer segments", the Company built a reserve of potential projects. In 2025, we achieved revenue of RMB3,755 million from small and medium-sized companies, reflecting a 20.57% increase compared to 2024. Revenue streams became increasingly diversified.

During the Reporting Period, the revenue derived from overseas customers reached RMB4,921 million, showing a year-on-year growth of 14.85%. The Company's revenue from domestic customers was RMB1,749 million, experiencing a year-on-year increase of 15.09%.



i. Small Molecule CDMO Business

The global small molecule CDMO business features a broad market with low industry concentration and a sustained increase in industry penetration. The growing incidence of chronic diseases and aging population trend propel the demand for innovative small molecule drugs. The pharmaceutical industry's focus on developing novel, more effective targeted therapies has resulted in increased product pipelines and the need for innovative drug delivery methods. The trend of global small molecule CDMO demand shifting to emerging markets, particularly to China, is likely to continue in the coming years.

The Company's small molecule CDMO business focuses on product stages characterized by stringent regulatory requirements and large-scale supply demands, with its projects spanning multiple major therapeutic areas, including oncology, antiviral, anti-infective, cardiovascular diseases, and diabetes. During the Reporting Period, the small molecule CDMO business achieved in-depth breakthroughs in core technologies such as high-throughput screening, continuous flow and photochemical and electrochemical, with an expanding portfolio of new technologies applied to its clinical and commercial projects.

Leveraging industry-leading technology advantages and first-class operational management and quality systems, along with a strong track record in project delivery, the small molecular CDMO business exhibited high-quality development momentum. During the Reporting Period, the recognized revenue reached RMB4,735 million, with a year-on-year increase of 3.59% and a gross profit margin of 46.45%. The Company delivered 59 commercialization projects and 515 clinical or pre-clinical stage projects, including 70 clinical phase III projects. During the Reporting Period, the Company participated in five small molecule GLP-1 clinical stage projects related to obesity, of which two are in late-stage clinical development. As at the date of this announcement, according to the current small molecule clinical stage orders in hand, the number of projects reaching process performance qualification ("**PPQ**") stage in 2026 reached 16.

ii. Emerging Business

Leveraging the industrial resources and competitive advantages accumulated in its small molecule CDMO business, the Company has rapidly advanced the market expansion and capacity development in emerging businesses, driving robust growth in its emerging businesses. During the Reporting Period, the Company achieved revenue of RMB1,929 million, representing a year-on-year increase of 57.30%, of which overseas revenue was RMB852 million, surging by over 240% year-on-year. The overall gross profit margin of emerging businesses reached 29.65%, a year-on-year increase of 8.47 percentage points.

Chemical Macromolecule CDMO Business

During the Reporting Period, revenue of the chemical macromolecule CDMO business amounted to RMB1,028 million, soaring by 123.72%. As at the date of this announcement, the order backlog has surged by 127.59% compared to the same period last year, with overseas orders taking up 58.42%.

The Company supported 52 clinical-stage peptide drugs, of which a total of 19 projects focused on obesity related, with 8 projects in clinical late stage. During the Reporting Period, the first peptide project was approved for listing and commenced commercial supply. Drawing on the order backlog, the number of PPQ projects in the peptide business is expected to be four in 2026. Continuing to advance the development of oligonucleotide projects, the Company facilitated 69 clinical-stage projects, of which 20 are in late-stage clinical development. At the same time, the Company extensively engaged in nucleic acid-conjugated drug projects based on novel delivery technologies, including antibody-oligonucleotide conjugates ("**AOC**"), peptide-oligonucleotide conjugate ("**POC**"), aptamer drug conjugates ("**ApDC**"), Oligo-lipid, etc. In addition, the toxin linker business provided services for 36 clinical-stage projects, among which six are PPQ projects. Our first ADC drug passed the pre-approval inspection ("**PAI**") and entered the commercialization stage. Furthermore, four projects are expected to enter commercialization sequentially in 2026.

Biological Macromolecule CDMO Business

During the Reporting Period, the biological macromolecule CDMO business generated revenue of RMB294 million, reflecting a robust 95.76% year-on-year increase, of which 39.55% was derived from overseas projects. A total of 130 projects were executed, including 5 BLA projects, 46 IND projects and nearly 70 R&D service projects. The Company established the PPQ project platform system and successfully completed its first PPQ production. As at the date of this announcement, the order backlog has grown by 55.56% year-on-year, with overseas orders accounting for 39.92%.

During the Reporting Period, the Company secured its first one-stop service project for antibody-peptide conjugate ("**APC**") drugs, the first high-concentration antibody drug production IND project, and contributed to the successful out-licensing of the first late-stage ADC BLA project, and assisted multiple leading domestic clients in the successful global expansion of several projects, demonstrating the ability to deliver global services. A total of 36 audits were conducted throughout the year, including multiple audits by multinational corporation ("**MNC**") clients, with a 100% client audit pass rate. In addition, the Company supported many companies in obtaining FDA clinical approval and FDA IND approval.

The Company actively built ToolBox capabilities, undertook and participated in multiple large-scale forums and keynote speeches, demonstrating the external influence of AsymBio. AsymBio conjugated drug development platform was successfully shortlisted for the 12th World ADC Awards "Best ADC Platform Technology", underscoring AsymBio's outstanding position in the global ADC CDMO field.

Drug Product CDMO Business

During the Reporting Period, the drug product CDMO business realized revenue of RMB284 million, an increase of 18.44% year-on-year. The Company progressed 200 projects and expanded its client base by 56 new clients, including nearly 20 overseas clients. Leveraging the reliable quality system, the Company successfully passed the inspections by FDA, PMDA, NMPA and other regulatory authorities during the Reporting Period. The commercialization of drug production recorded substantial progress. During the Reporting Period, seven new drug product commercialization projects were added, bringing the total number of drug product commercialization projects to nine, including two projects serving overseas markets, continuing to accelerate globalization. As at the date of this announcement, the order backlog has risen by 49.13% year-on-year, of which overseas orders accounted for 29.27%.

The Company's drug product technology platforms achieved a series of breakthroughs and continued to expand its novel drug product projects. The nanocrystalline technology platform was continuously being consolidated, along with several oral nanocrystalline projects successfully achieving clinical delivery, and the delivery of sterile nanocrystalline suspension projects was completed. The topical drug product platform remained committed to strengthening, while the clinical delivery of multiple projects was accomplished. The complex drug product platform, covering dosage forms such as liposomes, nanoparticles, long-acting and sustained-release peptide injection, successfully delivered multiple orders. The Company established a microtablet technology platform and commenced the supply of clinical enteric-coated microtablet products. The small nucleic acid drug product platform maintained its leading position, with the number of projects exceeding one hundred, many of which entered the clinical late-stage. The technology platform of sterile in-situ gel, nasal spray and eye drops continued to empower operations, successfully completing the delivery of multiple projects.

Clinical Research Organization (CRO) Service Business

During the Reporting Period, clinical research organization ("**CRO**") service business generated revenue of RMB282 million, growing by 26.53% year-on-year. The Company assisted its customers in successfully obtaining three implied FDA IND approvals and supported 23 projects in obtaining implied China IND approvals. The Company undertook 216 new projects, achieving an increase of over 50% in newly initiated Phase II/III clinical research projects. Overseas business continued to make progress with 15 new overseas applications and clinical orders. Among these, projects from overseas clients undertaken in China have entered the execution phase, significantly enhancing the Company's penetration in international markets. The Company strengthened its established expertise in traditional strengths such as oncology, immunology, infectious diseases, orthopedics, respiratory system, hematology and gynecology. In addition, the Company sustained ongoing in-depth exploration in rare diseases and achieved new breakthroughs in psychiatry, anesthesiology, neurology, endocrinology and metabolism, ophthalmology, cardiovascular, gastroenterology, dermatology and nephrology. As at the end of the Reporting Period, the Company was conducting 294 clinical research projects, including 122 Phase II and later-stage clinical projects.

In terms of data intelligence, the Company expanded the application of the full-process intelligent pharmacovigilance platform to more than 40 innovative drug clinical projects, and integrated a fully in-house developed intelligent question-and-answer robot (Chat BI) to enable natural language interaction with the database. At the same time, the Company explored Artificial Intelligence ("**AI**") solutions for clinical trial plans and reports (CSP/CSR) together with multiple clients, and test results showed a significant improvement in writing efficiency and quality.

Synthetic Biology and Export of New Technologies Business

During the Reporting Period, the synthetic biology business secured 34 new clients. The Company successfully developed multiple enzyme products, enabling nearly a thousand-fold improvement in enzyme activity within four weeks and significantly enhancing R&D efficiency. The Company enabled the industrial application of the "Enzymatic Ligation-based Oligonucleotide Synthesis" technology on the core technology of nucleic acid synthesis. Compared with traditional solid-phase chemical synthesis, the Company substantially improved efficiency. The immobilized enzyme continuous reaction technology achieved commercial application across a range of commonly used enzyme classes, including hydrolases, oxidoreductases, and transferases, effectively helping partner companies reduce production costs and minimize the emission of the three types of waste.

With respect to the cell engineering technology platform, leveraging self-engineered high-performance chassis strains, the Company integrated end-to-end technologies including multi-omics analysis, fermentation process optimization and separation and purification. The Company achieved efficient production of products such as salidroside, resveratrol, sclareol and bakuchiol.

With regard to the microbial expression platform of biological macromolecules, the Company successfully built a high-throughput screening platform for fillers and a design of experiments ("**DOE**") technology platform for protein purification, which can rapidly complete the screening of purification medium within two to three weeks and develop a robust purification process within six to eight weeks. The 500L GMP plant officially started operation and successfully delivered three IND projects.

In terms of continuous reaction technology export, the Company continued to implement projects for customers across fine chemical fields such as pharmaceuticals, pesticides, and materials in an orderly manner. The Company is currently fulfilling ten active orders and continuously expanding the reserve of self-developed projects. Efforts are now underway to optimize the management and operation system, building a professional multidisciplinary project team spanning chemistry, chemical engineering, equipment, and engineering, focusing on enhancing efficiency and service capabilities.

iii. R&D Platform Construction

As a technology driven company, our key success lies in seamlessly integrating cutting-edge technologies and their industrial application, continuously strengthening our technological competitiveness, and solidifying our leading position in the CDMO industry. Leveraging our multiple in-house innovative R&D platforms, our process development team provides customized solutions for our customers using cutting-edge technologies and know-how.

With a strategic emphasis on the "development" component of CDMO services, Asymchem has been focusing on developing a top-tier technology platform. As at the end of the Reporting Period, our Group has obtained a total of 577 authorized patents both domestically and internationally, including 440 patents in China and 137 patents in other jurisdictions such as the U.S., the European Union, Japan, South Korea, and India. Among these, 205 are in the field of synthetic biology and 210 are in the field of continuous flow technology, respectively. Especially for the latter, our Company was one of the earliest companies to apply continuous manufacturing in drug production and is also one of the few that can apply the technology at the ton-level instead of gram-level. The applications of these patents simplified procedures, reduced processing duration and raw material cost and gave Asymchem a strong competitive edge. This continued focus on R&D has made Asymchem one of the few companies that can provide a one-stop solution platform.

Multiple technology centers of the Group are dedicated to cultivating cutting-edge technologies and spearheading technical innovation, in order to offer robust technical support for the Company's new strategic direction and expansion.

Throughout the Reporting Period, in terms of continuous reactions and biosynthesis, the Company achieved significant results in technologies such as continuous synthesis, peptide TFA cleavage, and recombinant synthesis. Our research papers on new technologies have been published multiple times in the most authoritative scientific journals in the field of natural sciences such as Nature, as well as other important journals in the industry including Journal of the American Chemical Society, Angewandte Chemie (Germany Applied Chemistry), Journal of Organic Chemistry, Organic Letters, and other leading international journals. By the end of the Reporting Period, a total of 51 papers have been published, among which 17 have impact factors exceeding ten.

For the year ended 31 December 2025, our R&D expenses were RMB593 million, representing 8.89% of our total revenue. As we anticipate future revenue growth, we also plan to allocate a proportional increase in our R&D expenses.

iv. Investments and Constructions of Capacity Expansion

We possess advanced manufacturing sites which were built from the ground up to stringent standards. As at 31 December 2025, we had multiple R&D centres, manufacturing sites, production facilities and branches/offices across China, the United States, the United Kingdom, and other regions, and secured its first research and manufacturing site in Europe, as shown below:

The Company continued to strengthen its technical reserves in peptides and oligonucleotides, and achieved breakthroughs in technologies such as fragment enzyme ligation, TAG-assisted liquid-phase synthesis, continuous purification, and continuous cleavage, enabling more efficient, greener, more accessible, and more sustainable drug production, while continuously delivering deep empowerment to customers. As at the end of the Reporting Period, the total peptide solid-phase reaction synthesis capacity is 45,000L, and will expand to 69,000L by the end of 2026 to meet the future production capacity demand of the order backlog. Furthermore, the oligonucleotide capacity reached 120 mol and is projected to increase to 180 mol by the end of June 2026 to enhance project delivery capacities. Continuing to advance the high-potency manufacturing capacity, the Company completed the construction and put into operation an additional Occupational Exposure Band 5 ("**OEB5**") plant and R&D building, significantly strengthening the delivery capacity for commercial-scale highly active drug projects.

The first phase of the commercialized antibody plant in Fengxian has commenced operations, effectively addressing the needs of the global biopharmaceutical market. The first phase of the commercialized ADC workshop in Fengxian is expected to be delivered in the second quarter of 2026, further expanding the commercial capacity of ADCs.

The construction of drug product capacity advanced steadily. The construction of the β-lactam solid drug product workshop and the pre-filled syringes drug product workshop were brought into use under GMP standards and delivered multiple projects. The commercialized blow-fill-seal (BFS) facility and cartridge drug product facility progressed on schedule and are expected to be put into production in the second quarter of 2026. Furthermore, construction of the pharmaceutical spray dryer ("**PSD-3**") workshop was initiated and is scheduled to begin operations by the end of 2026, providing stronger manufacturing support for the drug product business.

In terms of synthetic biology, the Company was equipped with a full-scale production line from 50L to 5,000L that fulfils GMP standards. A dedicated, independent bio-fermentation facility with a total area of approximately 17,000 square meters has been fully commissioned, which can meet the production needs of multiple types of products, including enzymes, recombinant proteins, peptides and bio-based small molecules, at the same time.

We generally expand and build our development and manufacturing facilities in anticipation of increased demand arising from new customer engagements and strategic plans. For details, please refer to the section headed "Use of Net Proceeds from the Issuance of Securities" in this announcement. We are strategically focusing on further expanding our overseas capacity in the small molecule business segment. Recognizing the growing global demand for our services, we aim to strengthen our presence in international markets by establishing production facilities abroad or through the acquisition of a suitable production base. This approach will enable us to effectively cater to the needs of our overseas core client base and enhance our competitiveness on a global scale. By leveraging our expertise, advanced technologies, and efficient processes, we are committed to providing high-quality small molecule CDMO solutions to customers worldwide. Through overseas capacity expansion, we aim to optimize our supply chain, shorten lead times, and improve overall operational efficiency. This strategic initiative aligns with our commitment to delivering exceptional services to our clients while solidifying our position as a leader in the small molecule CDMO industry.

v. Cultivation of Our Team of Talents

An effective talent management strategy is required to succeed in the highly competitive and rapidly evolving pharmaceutical industry. As a leading CDMO company, we recognize the importance of cultivating and retaining a diverse pool of professionals with multi-disciplinary expertise. Our global team possesses advanced technical knowledge, strong execution capabilities, and a customer-centric culture, which enables us to help our clients overcome complex process development and manufacturing challenges through teamwork and collaboration. We attract and cultivate talent globally by offering a collaborative work environment, cutting-edge projects, a reasonable and competitive remuneration package, and a community-driven career development platform.

In 2025, to achieve our goals, we implemented a tailored talent strategy for each of our key business segments. We offered internal training programs to equip our employees with the latest technology advancements, industry know-how, and regulatory developments. We inspired our employees to develop a strong sense of ownership and encouraged them to work on industry-defining and landmark projects. Moreover, we offered competitive compensation and compelling career development opportunities to motivate and retain our high-quality talent base.

The Company firmly upholds and adheres to the strategy of talent introduction by optimizing various employment mechanisms such as talent selection, training, utilization, evaluation, incentive, and retention. We established talent management systems for small molecule CDMO business and strategic emerging business and accelerated the introduction of talents including business leaders and key technical positions in emerging business segments. In 2025, we recruited 201 experts, approximately 50% of whom holding Ph.D degrees. As at 31 December 2025, our total workforce comprised 10,617 employees (including senior management and excluding interns, individuals with disabilities and rehired retirees, etc.), with around 78.2% possessing an undergraduate degree and/or above, and 23.9% possessing a master's degree/Ph.D. and/or above. Additionally, the R&D and analyst team consisted of 5,243 employees, accounting for approximately 49.38% of the total workforce, with 96.45% holding at least an undergraduate degree. Among them, 1,728 had a master's degree and 308 held a Ph.D. Notably, the proportion of senior researchers with a master's degree and Ph.D. diploma within the R&D team increased by approximately 0.89% year-on-year. We believe that our employees are a valuable asset of the Company, and we serve as the platform for employees to showcase their talents and realize their values.

In terms of talent risk management, we have established the Values and Code of Conduct at the Company level, integrating the Supply Chain Code of Conduct to ensure compliance and monitor business development comprehensively, as well as provide fundamental principles and guidelines for employees to align their actions with the Company's values. The Diversity, Equity and Inclusion Policy established for employees undergoes periodic reviews and updates as the Company grows, aiming to safeguard the fundamental rights and interests of our employees.

vi. Social Responsibility and Sustainable Development

As a listed company with social responsibility, Asymchem stays committed to offering quality products and professional services to its partners. The Company, in strict accordance with the provisions of relevant laws and regulations and in light of its particular conditions, undertakes the responsibilities to Shareholders, partners, employees, society and other stakeholders. The Company gives back to society through practical action and fosters a harmonious environment for development, to achieve the ultimate goal of sustainable development.

Under the Asymchem sustainability model, there are four major elements for synergy: customer empowerment, civic responsibility, community building, and protecting the earth. As a leading CDMO service provider in China, we are committed to global pharmaceutical technology innovation and commercial application. We are sincerely dedicated to providing customers with quality products and professional services, and actively fulfill our responsibilities to our employees, shareholders, investors, and other stakeholders. While maximizing economic benefits, we pursue the collaborative development of social benefits and environmental protection in order to achieve sustainable development. We are highly focused on protecting the interests of our shareholders, customers, all employees, suppliers, and other interest groups and stakeholders. We have established an improved corporate governance structure, a complete internal control system, and a platform to interact with investors, to assure all Shareholders of fairness, promptness, justice, transparency, and openness.

In our daily operations, we are committed to our customer-centric approach and provide our customers with high-quality services through continuous development of technologies and processes. In terms of employee rights and interests, we comply in all material respects with the PRC Company Law, Labor Contract Law and other laws and regulations, and have formed a management philosophy that "there will be no quality products without satisfactory employees", showing that we care about the health, safety, and satisfaction of our employees. At the same time, we maintain good interaction with suppliers, especially suppliers with long-term cooperative relationships. We fully understand that most of our overseas clients have established comprehensive environmental, social and governance ("**ESG**") management objectives, which will be communicated to Asymchem. In particular, overseas customers have put forward clear ESG expectations for supply chain companies. As part of the supply chain, we strive for the best efforts to balance the requirements while operating the business to maximize the mutual benefit.

We have established "Teda-Asymchem Scholarship" in several colleges and universities to support the academic study and research of college students, demonstrating our concern for the growth of young students and our encouragement towards them. Particularly, we have set up several scholarships for college students facing financial hardship in many universities and colleges. We have also created several fellowships for outstanding achievements in drug synthesis in some universities and colleges and sponsored various academic conferences and symposiums.

For more details regarding social responsibility and sustainable development information, please refer to the 2025 ESG Report published in April 2026.

II. FINANCIAL REVIEW

In 2025, the Company realized revenue of RMB6,670.18 million, representing an increase of 14.91% compared to the same period last year. The gross profit margin in 2025 was 41.59%, up by 0.56 percentage points from the same period last year. The adjusted net profit attributable to shareholders of the listed company amounted to RMB1,253.49 million, representing an increase of 56.09% compared with 2024. During the Reporting Period, the small molecule CDMO business generated revenue of RMB4,734.65 million, a year-on-year increase of 3.59%. Revenue from the emerging business was RMB1,929.13 million in 2025, an increase of 57.30% from the same period last year. Our revenue in foreign countries (including North America, Europe, and Asia Pacific except China) reached RMB4,920.88 million in 2025, representing an increase of 14.85% from the same period last year, and domestic revenue reached RMB1,749.30 million in 2025, showing an increase of 15.09% from the same period last year. The Company continued to invest in the R&D platform, with an expenditure of RMB593.26 million in 2025, a decrease of 3.45% from 2024, accounting for 8.89% of the total revenue.

i. Revenue

During the Reporting Period, the Group's revenue by product categories was as follows:

	2025		2024		Change ratio
	RMB'000	**Proportion**	*RMB'000*	Proportion	*%*
Small molecule CDMO business	**4,734,651**	**70.98%**	4,570,728	78.74%	3.59
Emerging business	**1,929,130**	**28.92%**	1,226,374	21.13%	57.30
Total revenue from principal business	**6,663,781**	**99.90%**	5,797,102	99.87%	**14.95**
Other businesses	**6,400**	**0.10%**	7,555	0.13%	(15.29)
Total revenue	**6,670,181**	**100.00%**	5,804,657	100.00%	14.91

The Company's R&D, production, analysis, supply chain management, quality and other departments and teams achieved seamless cooperation and worked in coordination to fully satisfy the needs of customers for pharmaceutical supply, further enhancing the level of fine management and the advantages of the platform system. The Company continuously developed key processes and technologies for green pharmaceuticals and increased the use of new technologies and intelligent equipment to further enhance its competitive advantage in the commercialization of small molecule CDMO business. Many industry-leading commercialization projects were continuously implemented, and the Company's strong track record in delivery will further drive deeper collaboration with numerous domestic and international clients on commercial projects. During the Reporting Period, the Company had a total of 574 small molecule CDMO projects for which revenue was recognized, generating revenue of RMB4,734.65 million, representing a year-on-year increase of 3.59%.

During the Reporting Period, the strategic emerging segments recorded revenue of RMB1,929.13 million, representing a year-on-year increase of 57.30%. The chemical macromolecule CDMO business (including peptides, oligonucleotides, toxin linkers and lipids) achieved revenue of RMB1,027.89 million in 2025, representing a year-on-year increase of over 120%. The drug product CDMO business achieved revenue of RMB284.38 million in 2025, representing a year-on-year increase of 18.44%. The CRO business generated revenue of RMB282.14 million, achieving a growth of 26.53% year-on-year. The biological macromolecule CDMO business achieved revenue of RMB294.50 million in 2025, representing a year-on-year increase of 95.76%.

During the Reporting Period, the Company's revenue by countries or regions where our customer operates was as follows:

	2025		2024		Change ratio
	RMB'000	**Proportion**	*RMB'000*	Proportion	%
Domestic (China)	**1,742,902**	**26.13%**	1,512,353	26.05%	15.24
Foreign countries (including North America, Europe, and Asia Pacific except China)	**4,920,879**	**73.77%**	4,284,749	73.82%	14.85
Total revenue from principal business	**6,663,781**	**99.90%**	5,797,102	99.87%	14.95
Domestic revenue from other businesses	**6,400**	**0.10%**	7,555	0.13%	(15.29)
Total revenue	**6,670,181**	**100.00%**	5,804,657	100.00%	14.91

Our revenue from principal business in the domestic (China) market increased by 15.24% compared with the same period last year. Our revenue in foreign countries (including North America, Europe, and Asia Pacific except China) reached RMB4,920.88 million in 2025, representing an increase of 14.85% from the same period of 2024. The Group continued to prioritize market development and made positive progress in market expansion. During the Reporting Period, revenue from American customers amounted to RMB3,430.52 million, representing a year-on-year increase of 1.77%; revenue from Asia Pacific (except China) customers amounted to RMB292.83 million, representing a year-on-year increase of 64.17%; revenue from European customers amounted to RMB1,197.53 million, representing a year-on-year increase of 62.83%.

ii. Cost of Sales and Services

Our cost of sales and services includes costs of raw materials, direct personnel costs, manufacturing expenses and other related expenditures. Raw material costs cover direct and indirect materials required for production. Manufacturing expenses include depreciation of plant and equipment, energy costs, and testing and release expenses, among others. The category of "Others" includes transportation and insurance costs directly linked to sales, as well as associated taxes and fees. In 2025, our cost of sales and services was RMB3,896.39 million, representing an increase of 13.83% compared to the same period last year, largely in line with the increase in revenue in 2025 compared to the same period last year.

During the Reporting Period, the Company's cost by revenue type was as follows:

	2025	2024	Change ratio
	RMB'000	*RMB'000*	*%*
Small molecule CDMO business	**2,535,379**	2,450,302	3.47
Emerging business	**1,357,144**	966,663	40.39
Total cost of principal business	**3,892,523**	3,416,965	13.92
Other business costs	**3,862**	5,982	(35.44)
Total operating cost	**3,896,385**	3,422,947	13.83

iii. Gross Profit and Gross Profit Margin

During the Reporting Period, the Company's gross profit margin of principal business by product categories was as follows:

	2025	2024	Change
	%	*%*	*%*
Small molecule CDMO business	**46.45**	46.39	0.06
Emerging business	**29.65**	21.18	8.47
Total gross profit margin of principal business	**41.59**	41.06	0.53

During the Reporting Period, the Group's revenue of principal business increased by 14.95% and the cost increased by 13.92%, leading to the increase of principal business gross profit margin by 0.53 percentage points compared with the same period last year. Gross profit margin of the Company in 2025 increased by 0.56 percentage points compared with the same period last year.

The gross profit margin for small molecule CDMO business stood at 46.45%, reflecting an increase of 0.06 percentage points compared to last year. Similarly, the gross profit margin for emerging business stood at 29.65%, reflecting an increase of 8.47 percentage points compared to last year, benefiting from the growth of emerging business revenue, the improvement in operational efficiency and the increase in capacity utilization.

During the Reporting Period, the Company's gross profit margin of principal business by countries or regions where our customers operate was as follows:

	2025	2024	Change
	%	%	%
Domestic (China)	**21.37**	19.90	1.47
Foreign countries (including North America, Europe, and Asia Pacific except China)	**48.75**	48.52	0.23
Total gross profit margin of principal business	**41.59**	41.06	0.53

Our gross profit margin of principal business from domestic (China) in 2025 was 21.37%, which increased by 1.47 percentage points compared with the same period last year. Our gross profit margin of principal business from foreign countries (including North America, Europe, and Asia Pacific except China) in 2025 was 48.75%, with an increase of 0.23 percentage points compared to the same period last year.

iv. Other Income and Gains

The decrease in other income and gains from RMB480.72 million in 2024 to RMB392.35 million in 2025 was primarily attributed to the exchange losses and the decrease in interest income.

v. Selling and Marketing Expenses

In 2025, our selling and marketing expenses were RMB210.44 million, demonstrating a decrease of 13.54% from the same period last year, mainly due to the ongoing implementation of cost reduction and efficiency improvement initiatives, years of in-depth market cultivation and the synergy effects of "deepening cooperation with major clients", with a particular focus on optimizing marketing and promotional expenses during the Reporting Period.

vi. Administrative Expenses

Our administrative expenses in 2025 were RMB801.87 million, representing a decrease of 6.91% from RMB861.42 million for the same period last year, mainly attributable to the ongoing implementation of cost reduction and efficiency improvement measures.

vii. R&D Expenses

Our R&D expenses amounted to RMB593.26 million in 2025, representing a decrease of 3.45% compared with the same period last year. The decrease was primarily attributable to the Group's more focused direction and prioritization of R&D investment in 2025. While remaining committed to its core principle of being technology-driven, the Group continued to invest in technology innovation and independent R&D of core technologies, foster multiple innovative R&D platforms, increase R&D investment in in key areas, and align R&D investment with the Group's future development strategy.

viii. Impairment Loss on Financial and Contract Assets

The Group recorded an impairment provision for credit losses on financial assets measured and recognized using the expected credit loss approach. In 2025, our impairment losses amounted to approximately RMB72.61 million, compared with the RMB11.67 million in 2024, mainly attributable to the increase in the balance of trade receivables at the end of the current period, which was mainly caused by the increase in revenue.

ix. Finance Costs

Our finance costs primarily consist of interest expenses on lease liabilities. In 2025, our finance costs totaled RMB12.75 million, representing an increase of 34.15% compared with RMB9.51 million for the same period last year. The increase was mainly attributable to the increase in right-of-use assets compared with last year.

x. Income Tax Expense

Our income tax expense amounted to RMB159.74 million in 2025, reflecting an increase of 16.92%. This increase aligns with the Group's profit growth trend and is primarily attributed to the increase in revenue.

xi. Net Profit and Net Profit Margin

Our net profit increased by 20.40% from RMB935.76 million in 2024 to RMB1,126.64 million in 2025. In 2025, the net profit attributable to shareholders of the listed company amounted to RMB1,132.57 million, representing an increase of 19.35% compared with RMB948.95 million in 2024. In 2025, the net profit margin attributable to shareholders of the listed company was 16.98%, representing an increase of 0.63 percentage points from 16.35% in 2024.

xii. Basic and Diluted Earnings per Share

Our basic earnings per Share increased from RMB2.69 in 2024 to RMB3.16 in 2025. Our diluted earnings per Share increased from RMB2.69 in 2024 to RMB3.16 in 2025. The increase in basic and diluted earnings per Share was mainly due to the increase in the net profit.

xiii. Liquidity and Financial Resources/Cash and Bank Balances

During the Reporting Period, the Group's operations and investments were supported by internal resources. The cash and bank balances of the Group, mainly denominated in RMB, as at 31 December 2025 increased by RMB531.54 million or 9.18% from 31 December 2024, mainly due to an increase in trade receivables collection and a decrease in short-term and low-risk wealth management products in the banks held by the Group. We believe the Group has sufficient liquidity to meet the requirements of its daily liquidity management and capital expenditure, and to manage internal operating cash flows.

As at 31 December 2025, certain of the Group's bank deposits were pledged or otherwise subject to restrictions in connection with principal of wealth management products in transit, as security for the Group's performance under contracts, or pursuant to freezing arrangements affecting certain deposits or funds as set out in the sub-section headed "xvii. Pledge of Assets" below. Such restricted deposits formed part of the Group's overall cash and bank balances, but were not freely available for general corporate use as at 31 December 2025. Notwithstanding the foregoing, the Directors believe that the Group maintained a sound liquidity position throughout the Reporting Period and had sufficient financial resources to meet its working capital requirements, capital expenditure commitments and other operational needs as they fell due.

As at 31 December 2025, we had bank borrowings of RMB0.00 million (as at 31 December 2024: approximately RMB0.00 million).

xiv. Analysis on Assets and Liabilities

	2025 ***RMB'000***	2024 *RMB'000*	Change ratio *%*	Reason
Current Assets				
Inventories	**1,470,882**	1,193,346	23.26	Primarily due to the fluctuations resulting from continuous delivery of orders.
Trade and bills receivables	**1,977,465**	1,836,887	7.65	Primarily due to the increase in revenue.
Prepayments, other receivables and other assets	**523,270**	586,795	(10.83)	Primarily due to the decrease in VAT recoverable.
Non-Current Assets				
Property, Plant and Equipment	**6,441,721**	5,939,832	8.45	Primarily resulting from the construction of strategic emerging segments and development of equipment and plant infrastructure for operation.
Deferred tax assets	**275,619**	248,353	10.98	Primarily due to the increase in deferred tax assets recognized for deductible losses.
Prepayments other receivables and other assets	**446,007**	482,409	(7.55)	Primarily attributed to the due date of time deposits.
Current Liabilities				
Other payables and accruals	**1,247,315**	1,166,097	6.96	Primarily attributed to the increase in the liability for restricted Share repurchase.
Financial liabilities at FVPL	**9,836**	–	N/A	Including derivative financial instrument in relation to foreign exchange swaps.
Tax Payable	**69,472**	50,177	38.45	Mainly due to the increase in profit.
Non-Current Liabilities				
Deferred income	**294,734**	298,622	(1.30)	Including grants received during the Reporting Period.
Deferred tax liabilities	**111,604**	134,703	(17.15)	Mainly recorded in respect of taxable temporary differences existing in the accelerated depreciation of fixed assets.

xv. Investment Analysis & Income Analysis of Long-term Equity Investment Under Equity Method

Financial assets at fair value through profit or loss (current portion and non-current portion)

Financial assets at fair value through profit or loss mainly consisted of short-term and low-risk wealth management products purchased from banks and investment in Sany Zhongzhi (Tianjin) Venture Capital Center (L.P.) and Sany Zhongzhi Phase II (Tianjin) Venture Capital Center (L.P.). The Group's financial assets at fair value through profit or loss among current and non-current assets decreased from RMB1,697.57 million as at 31 December 2024 to RMB1,310.11 million as at 31 December 2025, mainly due to the decrease in the purchase of short-term and low-risk wealth management products from the banks.

Income from long-term equity investment under equity method

During the Reporting Period, the income from long-term equity investment under equity method amounted to RMB36.88 million, compared with the loss of RMB24.86 million in 2024. This increase was mainly driven by the changes in net assets of Tianjin Haihe Asymchem Biomedical Industry Innovation Investment Fund (Limited Partnership) (天津海河凱萊英生物醫藥產業創新投資基金(有限合夥)) ("**Haihe Asymchem Fund**"), Tianjin Haihe Asymchem Medical and Health Industry Investment Fund Partnership Enterprise (Limited Partnership) (天津海河凱萊英醫療健康產業投資基金合夥企業(有限合夥)) and Tianjin Yugen Medtech Co., Ltd ("**Yugen Medtech**"), in which the Group has invested, multiplied by the Group's shareholding ratio during the Reporting Period.

The Group's major joint venture, Haihe Asymchem Fund, primarily invests in the commercialization projects of the innovative field of biological medicine in the clinical stage. It is accounted for using the equity method and is strategically important to the Group's operations. The Group's other joint venture, Yugen Medtech, serves as a platform for scientific research CRO technology services, integrating innovative drug druggability research, pre-clinical and clinical stage systematic evaluation and registration services. It is also accounted for using the equity method and is strategically significant to the Group's operations. The Group's joint venture, Haihe Asymchem Medical and Health Fund, primarily invests in the innovative biopharmaceutical industry. It is accounted for using the equity method and is strategically important to the Group's operations.

xvi. Goodwill

Goodwill with net carrying amount of approximately RMB146.18 million as at 31 December 2025, (as at 31 December 2024: approximately RMB146.18 million) is acquired through the Group's acquisition of Tianjin GoalGen Biotechnology Co., Ltd. and Beijing Improve-Quality Technology Co., Ltd. Management of the Group performed impairment reviews of goodwill annually or more frequently if events or changes in circumstances indicated a potential impairment. The recoverable amounts of the cash-generating units to which the goodwill relates were determined based on the value in use. These calculations required the use of estimates and professional judgements, and the management of the Group involved an external valuer in these calculations. The Group has conducted impairment assessment on goodwill and no signs of impairment have been found.

xvii. Pledge of Assets

As at 31 December 2025, the net book value of buildings, land and equipment pledged by the Group was nil (as at 31 December 2024: nil). As at 31 December 2025, certain of the Group's bank deposits were pledged or otherwise restricted in connection with principal of wealth management products in transit, as security for contractual performance, or due to freezing arrangements applicable to certain deposits or funds, etc., which amounted to approximately RMB799.30 million (as at 31 December 2024: approximately RMB61.67 million).

xviii. Funding and Treasury Policies

The Group's finance department is responsible for the funding and treasury policies with regard to the overall business operation of the Group. The Company expects to fund its working capital and other capital requirements from a combination of various sources, including but not limited to internal financing and external financing at reasonable market rates. The Group continues to seek improvements in the return on equity and assets while maintaining prudent funding and treasury policies.

xix. Capital Expenditure

During the Reporting Period, the Group's capital expenditure on property, plant and equipment, land use rights and other intangible assets amounted to approximately RMB1,270.36 million (In 2024: approximately RMB1,130.01 million).

xx. Capital Commitments

As at 31 December 2025, the Group had capital commitments of approximately RMB587.24 million (as at 31 December 2024: approximately RMB414.68 million), all of which were used for the purchase of property, plant and equipment.

xxi. Contingent Liabilities

As at 31 December 2025, the Group did not have any material contingent liabilities and guarantees that would have a material impact on the financial position or operations of the Group.

xxii. Subsequent Events

Please refer to the paragraph "Corporate Governance and Other Information –Significant Events After the Reporting Period" of this announcement for the details.

xxiii. Gearing Ratio

As at 31 December 2025, the gearing ratio (calculated by dividing total liabilities by total assets) of the Group was 12.98% (as at 31 December 2024: 12.58%).

xxiv. Adjusted Non-IFRS Measures

To supplement the Group's consolidated financial statements which are presented in accordance with IFRS, the Group has provided adjusted net profit attributable to shareholders of the listed company and other data as additional financial measures, which are not required by or presented in accordance with IFRS. The Group believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends. The Group's management and investors may benefit from referring to these adjusted financial measures in assessing the Group's financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group's core business.

These non-IFRS financial measures, which the Group's management considers widely accepted and adopted in the industry, are provided to supplement the financial information prepared in accordance with IFRS. It is important to note that the presentation of these non-IFRS financial measures is not intended to be viewed in isolation or as a replacement for the IFRS-compliant financial information. Shareholders of the Group and potential investors should not solely rely on the adjusted results but should consider them in conjunction with the results reported under IFRS. Furthermore, these non-IFRS financial measures may not be directly comparable to similar measures used by other companies in the industry.

Additional data is provided below to reconcile adjusted net profit attributable to shareholders of the listed company and adjusted net profit margin attributable to shareholders of the listed company.

	2025	2024
	RMB'000	*RMB'000*
	(except percentage)	(except percentage)
Net profit attributable to the shareholders of the listed companies	**1,132,570**	948,950
Add: equity incentive amortization expense	**8,487**	15,414
Gain or loss on exchange rate fluctuations	**141,223**	(142,267)
Income tax effect	**(28,792)**	(19,028)
Adjusted net profit attributable to shareholders of the listed company	**1,253,488**	803,069
Adjusted net profit margin attributable to shareholders of the listed company	**18.79%**	13.83%

Notes:

In order to better reflect the key results of the Group's current business and operations, the adjusted net profit is based on the net profit attributable to shareholders of the listed company, and adjusted for the following matters:

(1) share-based compensation expense;

(2) foreign exchange gains or losses, primarily generated from revaluation of the assets and liabilities denominated in foreign currencies and the fair value change of foreign currency forward contracts, which the management believes is irrelevant to the Group's core business;

(3) the calculation of the adjusted net profit margin attributable to shareholders of the listed company is based on the above net profit attributable to shareholders of the listed company.

xxv. Foreign Exchange Risk

The majority of our revenues are derived from sales denominated in USD, while most of our service and operating costs and expenses are denominated in Renminbi, and our financial data is presented in Renminbi. Consequently, when the Renminbi strengthens against the USD, our margins come under pressure, potentially limiting our ability to price our service contracts, especially those with our U.S. customers, in currencies other than the USD.

The Group managed foreign exchange risk by conducting regular reviews of the Group's net foreign exchange exposures and would consider the use of foreign exchange contracts to mitigate such risk.

xxvi. Cash Flows

During the Reporting Period, the Group's net cash flows used in operating activities amounted to RMB1,407.59 million, representing an increase of RMB153.25 million compared to the Corresponding Period, mainly due to the increase in trade receivables collections.

During the Reporting Period, the Group's net cash flows used in investing activities amounted to RMB633.20 million, representing a decrease of RMB551.13 million compared to the Corresponding Period. The decrease was mainly due to the Group's reduced purchases of short-term and low-risk wealth management products in the banks and increased purchases of short-term pledged deposits, as well as the cash outflow for investments in associates of the Group in the same period last year.

During the Reporting Period, the Group's net cash flows used in financing activities amounted to RMB344.83 million, compared to RMB1,928.19 million for the net cash flows from financing activities in the Corresponding Period. The change was mainly due to the cash outflow for share repurchases in the same period last year.

xxvii. Capital Structure

Total equity attributable to Shareholders amounted to approximately RMB17,646.14 million as at 31 December 2025, compared to approximately RMB16,862.57 million as at 31 December 2024.

III. MATERIAL INVESTMENTS, ACQUISITIONS AND DISPOSALS

During the Reporting Period, the Group did not have any significant acquisitions or disposals of subsidiaries, associates and joint ventures of the Company. As at 31 December 2025, the Group did not hold any material investments (including any investment in an investee company with a value of 5% or more of the Group's total assets as at 31 December 2025).

IV. EMPLOYEES AND REMUNERATION POLICY

As at 31 December 2025, the Group had 10,617 employees (including senior management and excluding interns, individuals with disabilities and rehired retirees, etc.), whose salaries and allowances were determined based on their performance, experience and the prevailing market remuneration (as at 31 December 2024: 9,595 employees). We have invested in continuing education and training programs for all employees, which encompass a leadership

development program and a structured three-stage training program consisting of orientation training, probation period basic skills training and on-the-job training skills enhancement training. In response to multiple business demands, we have also tailored specific personnel training programs for targeted departments. These initiatives form a dedicated talent development framework aimed at cultivating specific talents within our management team and broader workforce to continuously elevating their skills and knowledge.

The Company is dedicated to developing a comprehensive and market-competitive compensation system for all employees, with a particular focus on key positions. We have established a multi-dimensional compensation structure comprising fixed salaries, performance-based bonuses, diverse welfare benefits and long-term incentives. We have made contributions to social security insurance funds (including pension insurance, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing provident funds, while providing diversified cash and non-cash benefits, such as supplementary commercial insurance, annual health check-ups and holiday benefits for our employees.

The Company also has the 2022 Employee Share Ownership Plan (the "**2022 ESOP**"), 2025 A Share Restricted Share Scheme (the "**2025 A Share Scheme**") and H Share Restricted Share Scheme in effect as at 31 December 2025.

During the Reporting Period, the Group did not experience any significant labour disputes or any difficulty in recruiting employees.

V. FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As at the date of this announcement, the Company did not have any existing plan for material investments or acquisition of capital assets.

VI. OUTLOOK AND PROSPECT

i. Industry Trend

In recent years, the outsourcing trend in the pharmaceutical CDMO industry has continued to deepen. Benefiting from increased R&D investment by pharmaceutical companies and the continued rise in outsourcing penetration, the global CDMO industry is experiencing sustained expansion. According to Frost & Sullivan, the global CDMO market size reached USD124.3 billion in 2025 and is projected to grow to USD231.0 billion by 2030, representing a compound annual growth rate (CAGR) of 13.2%. In the early 1990s, R&D pipelines were primarily concentrated within leading pharmaceutical companies, and outsourcing models were relatively simple, mainly serving as an extension of decentralized production capacity. As the global R&D landscape evolved, pipelines became increasingly dispersed, with the top 25 global pharmaceutical companies accounting for approximately 10% of R&D pipelines, while overall outsourcing penetration has exceeded 50%.

Accordingly, the role of pharmaceutical CDMOs has continued to evolve, gradually transitioning from merely extending external capacity to meeting the production demands driven by the rise of biotech companies after 2000, and later, following the growth of Chinese pharmaceutical companies after 2010, CDMOs have become key strategic partners within the pharmaceutical industry. With increasing molecular complexity and the scarcity of capacity for new modalities, including peptides, oligonucleotides, and antibody-drug conjugates – outsourcing penetration is expected to continue rising. CDMOs are also gradually shifting from decentralized to centralized models, with economies of scale becoming increasingly pronounced.

Based on data from Evaluate Pharma and BCG analysis, while small-molecule drugs remain the market mainstream, new modalities are increasingly becoming a focal point for the industry. Several submarkets show significant growth potential: (i) Obesity drugs: The peptide-centric obesity market has reached a scale of hundreds of billions, encompassing single-target injections, multi-target combinations, oral small molecules, long-acting GLP-1 drugs, and combination therapies. Nucleic acid drugs are also beginning to enter the weight management space. This market is expected to remain long-term, exerting a profound impact on the industry ecosystem. Oral formulations are viewed as the future mainstream direction, and the Group will continue to monitor and strategically position itself in these opportunities; and (ii) Oligonucleotide drugs: In recent years, several MNCs have acquired small nucleic acid-targeting pipeline companies for nearly US$10 billion, marking the expansion of oligonucleotide drugs from rare diseases into common diseases. In addition, an MNC licensed an AOC pipeline in a deal worth approximately US$10 billion, highlighting the evolution of oligonucleotide drugs from liver-targeted to systemic delivery. The application of diverse carrier technologies – including peptides, antibodies, small molecules, and fatty acid carriers – enables oligonucleotide drugs to target multiple tissues, further unlocking market potential.

According to data from Pharmacube, China's innovative drug sector is undergoing a reversal in competitiveness. The proportion of molecules introduced into China by MNCs has risen from nearly zero a few years ago to approximately one-third. Chinese innovative drugs now account for 30% of global clinical trials, second only to the United States, and in 2025, upfront payments for business development ("**BD**") transactions by Chinese companies are expected to account for 40% of the global total. The outsourcing demand from China's innovative drug sector presents substantial growth opportunities for CDMOs.

In summary, as outsourcing demand continues to grow and new drug modalities emerge, the strategic position of CDMOs in the global pharmaceutical value chain is expected to further strengthen.

ii. 2026 Strategy Highlights

The CDMO industry has shown a positive trend. After the Company returned to a growth trajectory in 2025, orders will continue to grow while operations remain favorable. The Company expects its operating performance in 2026 to show an accelerated growth trend with estimated revenue growth of 19-22%.

In 2026, the Company will vigorously promote the development of emerging businesses such as chemical macromolecule and biological macromolecule CDMO businesses, firmly seizing market opportunities to continuously generate incremental contributions in these areas. Meanwhile, it will promote the steady development of the small molecule business, laying a solid foundation for sustained growth in performance.

Focusing on improving operational efficiency, the strategy will shift from cost reduction and efficiency enhancement to cost control and efficiency improvement, effectively increasing profit margins and business competitiveness.

iii. Long-term Strategy

In 2025, despite the complex and volatile international landscape and the slow recovery of financing for small and medium-sized pharmaceutical companies both domestically and abroad, AI technology has accelerated the development of innovative drugs, bringing new opportunities and challenges to domestic CDMO companies, including Asymchem. Following years of rapid growth, the Company now faces an urgent need to upgrade its management system to drive cost reduction and efficiency improvements. At the same time, the Company must expedite the expansion of its overseas production capacity and deepen cooperation with overseas clients, especially multinational pharmaceutical companies. Although challenges persist, the industry as a whole has gradually emerged from its most difficult period. The market has been significantly boosted by the growth potential of GLP-1 drugs, and the ongoing activity in drug categories such as ADC and small nucleic acids has also brought fresh opportunities to the industry. Moreover, the trend of specialized division of labor in the global pharmaceutical industry remains unchanged. In the face of both challenges and opportunities, the Company will focus on the following key initiatives in recent years:

Accelerating Capacity Expansion: Expanding global footprint in production capacities

As a leading Chinese CDMO company that was originally established in the United States early on and later built its own production capacities upon returning to China, Asymchem has been seeking suitable production capacities or bases outside China over the years to maintain robust production support. We successfully obtained our first R&D and pilot production base in Europe. This will expand our business areas with competitive advantages, extend our service radius, and deepen cooperation with overseas customers, especially multinational pharmaceutical companies. We anticipate utilizing this as a lever to broaden our service areas and customer base, further attract domestic and international orders, continuously penetrate into the international market, accelerate our global footprint, and thereby further ensure future growth certainty and increase order visibility.

Optimizing Profitability: Reinforcing backbone business and overall operation

Adhering to years of leading professional accumulation and profound experience in the small molecule CDMO industry, Asymchem will (i) consistently prioritize steadily increasing the gross profit margin of the small molecule CDMO business, strictly control production costs by improving efficiency and management optimization, further reduce raw material costs through technological research and development; (ii) under the premise of prioritizing development, reasonably control the various costs of emerging businesses, especially the growth of fixed costs; and (iii) rigorously control unnecessary administrative expenses to optimize the overall profitability of the Company.

Building Capability: Advancing emerging services offerings

We will vigorously accelerate the development of emerging services, striving to significantly enhance delivery capabilities and swiftly expand overseas markets. We will (i) upgrade management and operational systems, allocate resources synergistically, focus on delivering emerging business projects and capability building; (ii) expedite the establishment of commercial production capacity for small nucleic acids, peptides, and ADCs, and achieve

further breakthroughs in commercial project undertakings; (iii) leverage recent technological accumulation and performance records, synergize with the Company's accumulated customer resources and reputation, accelerate the exploration of overseas markets for emerging businesses; and (iv) further enhance the design and manufacturing of continuous flow reaction equipment, vigorously promote the application of continuous flow technology in multiple fields and strengthen the cooperation model with clients for the output of continuous flow reaction technology.

Technology Driven: Strengthening R&D platform capabilities

We will (i) maintain a substantial commitment to research and development investment, establish an iteratively evolving research and development platform, create cross-department collaboration models for processes, engineering, and equipment, fortify process synthesis route design and optimization using state-of-the-art research and development methodologies to facilitate order fulfillment; (ii) continually bolster the development of synthetic biology technology platforms, advocate for the integration of these platforms across different sectors, and cultivate manufacturing capabilities for synthetic biology products; and (iii) prioritize research and application in intelligent technology, digital platform construction, etc., leveraging advanced control methods to drive the advancement of intelligent manufacturing technology and the implementation of intelligent production in factories.

Operational Excellence: Enhancing efficiency and cost-effectiveness through system upgrades

Looking back over the past decade, Asymchem has been able to seize opportunities every few years, undertaking and seamlessly completing high-quality orders with substantial amounts. In recent years, the rapid development of AI in the healthcare industry has presented both new challenges and opportunities for the Company. We will consistently enhance the organizational and procedural development of operational management systems to drive continuous improvements in management efficiency and reinforce the cultivation of corporate culture, while emphasizing a people-centric approach to recruitment, ongoing enhancement of management talent, refinement of incentive structures, productivity enhancement, fostering unity, and boosting overall staff effectiveness. Additionally, we will retain our focus on excelling in the implementation of management digitization and digital transformation.

iv. Core Advantages

Asymchem is a leading, technology-driven CDMO providing comprehensive solutions and services throughout the drug development and manufacturing process. Our Company has more than two decades of experience in small molecule drug development and manufacturing and has become an integral part of the global value chain for innovative drugs. With extensive know-how and advanced technologies, the Company has collaborated with diversified global pharmaceutical companies and has become the leading small molecule and new modality (peptide, oligonucleotide, ADC, etc.) CDMO in China.

Drawing on our extensive industry knowledge, well-established R&D platforms, manufacturing capabilities, and stellar reputation with customers, we have enhanced our CDMO offerings to encompass cutting-edge drug modalities. These include peptides, oligonucleotides, monoclonal antibodies ("**mAbs**"), ADCs and messenger RNA ("**mRNA**"). Furthermore, we have expanded our service portfolio to encompass chemical macromolecule CDMO solutions, drug product solutions, biosynthesis solutions, and clinical CRO solutions,

and the export of continuous flow technology and synthetic biology technology, collectively referred to as our emerging services. Our vision is to become a reliable partner for the global pharmaceutical industry providing superior one-stop CDMO services and solutions throughout the full lifecycle of drugs from their development to commercialization.

Leveraging our management team's global vision, strategic insight, and local expertise, Asymchem is well positioned to capture the growing trend of global CDMO outsourcing to China, with its technological leadership and extensive know-how, established long-term relationships with global leading biopharma/biotechnology companies, as well as service capability expansion into new modalities and service types. During the past few years, following the outbreak of public health emergency, the recent commercial contracts with a leading global pharma company have further validated our leading services and delivery capabilities, resulting in elevating the Company to the next level.

- **We have continued to develop as a technology driven CDMO providing comprehensive solutions with strong revenue growth performance of the flagship services through our small molecule and emerging business services.** Asymchem has amassed more than 20 years of experience and solidified its position in the small molecule business. Our collaborations with international multinational pharmaceutical companies have grown stronger. The gradual resumption of international business travel enables more clients to witness our capabilities firsthand, while an increasing number of advanced projects, including API verification initiatives, are successfully being implemented. We have effectively addressed external apprehensions regarding the partnerships between multinational pharmaceutical firms and Asymchem through tangible outcomes. Moreover, the enhancement of research and development production efficiency for small molecules, driven by collective efforts, coupled with ongoing cost reductions, ensures our sustained competitiveness. Serving as the foundational business of Asymchem, the prospects for small molecule CDMO remain positive for further growth.

  We strive to further advance our market leadership in the small molecule CDMO market through our established reputation, advanced R&D platforms, robust manufacturing capabilities and high-quality customer services for diversified multinational pharmaceutical companies and leading biotechnology companies across different jurisdictions. Derived from multiple business lines of the emerging services segment, we have focused on peptides and oligonucleotides in chemical macromolecules, captured the growth of biological macromolecules through integrated service for ADC, various conjugated drugs, and payload linkers, and promoted the export of continuous flow technology and synthetic biology technology. The two flagship technologies have evolved from individual components into full-fledged technological platforms. We can now offer external technology output, enabling partners from diverse fields to leverage our cutting-edge technological achievements to address their own pain points, leading to notable enhancements in efficiency and safety while significantly reducing costs. By leveraging the deep industry insights, we will continue to push forward emerging business lines. We believe this will drive our company's secondary growth curve by strengthening our strategic positioning in the obesity market, oligonucleotide drug category, and the antibody-conjugate innovative drug field in key therapeutics.

- **We have laid the groundwork for revenue growth and a broad project funnel through strong customer retention and an expanding customer base.** Our Company has been able to retain its top global pharma companies' client base, which consists of diversified multinational pharmaceutical companies, through cooperative relationships of more than ten consecutive years, which demonstrate very strong customer loyalty. Our Company is gaining traction in global pharmaceutical companies, small to midsize pharmaceutical companies and leading biotechnology companies by upholding a customer-centric business philosophy. The robust customer base with expansion allows us to have an extensive pipeline of projects at various stages, creating a broad funnel to maintain a steady stream of small molecule business segments and growth in emerging services. Our commercial stage projects and late-stage clinical projects continue to increase, which has substantially improved the stability and predictability of our revenue growth.

- **We have continued to focus on advancing and evolving multiple R&D platforms for technology leadership based on our customer-focused innovation.** With a strategic emphasis on the "development" component of CDMO, our Company has been focusing on developing a top-tier technology platform and is among the CDMO companies that contribute the most to R&D per Frost & Sullivan Analysis. Our Company was one of the earliest CDMOs to apply continuous flow technology in drug production and is also one of the few that can apply the technology at the ton-level instead of gram-level, leading to simplified procedures, reduced processing duration and raw material costs, enhancement of yield and safety, and ultimately delivering cost efficiencies to clients. As at the end of 2025, number of the Company's mid- and late-stage clinical projects and commercial-stage projects applied key technologies for green pharmaceuticals, generating favorable economic benefits and efficiency, including but not limited to continuous flow technology and synthetic biology technology. This continued focus on R&D has enabled Asymchem to maintain its competitive edge and technology leadership in the small molecule CDMO space and further development of emerging businesses. Meanwhile, promoting the export of green technologies, i.e. continuous flow technology and synthetic biology technology to external clients, allows Asymchem to enhance the industrial image, drive the industrial trend, and elevate to a higher level as a source of revenue through technology rather than customized manufacturing.

- **We have enhanced our first-class operational and quality management capabilities and delivery efficiency in projects, meeting the stringent requirements of clients and global industry standards and have built a decent industry reputation.** Our extensive expertise in process development and efficient delivery knowledge has made us the preferred choice for large clients. In recent years, we have optimized process development, analytical method development cycles, shortened production cycles, streamlined process systems, and applied automation and AI technologies. We can expediently solve a variety of complex process challenges in the scale-up production of innovative drugs, accelerating the clinical development process and providing high-quality enhancements in yield and stable production during the commercial stage. Based on years of large-scale manufacturing experience, we have established a comprehensive, rigorous Current Good Manufacture Practices ("**cGMP**") quality system and a first-class environmental, health, and safety ("**EHS**") and quality assurance ("**QA**") system. In the past, we have an outstanding track record of EHS and Environmental Assessment ("**EA**") system compliance and further extensive improvement and development in response to the rapid upgrading of supplier requirements by several clients, i.e. multiple pharmaceutical companies through their individual ESG standards.

- **We have further enhanced our fully integrated platform from different aspects including market-oriented planning, talent introduction and capacity expansion.** In 2025, while keeping our cost-effectiveness and cost-efficiency as one of our core principles, we continuously strengthened talent recruitment and cultivation as the emerging business is accelerating, and constantly improved the employment mechanisms, accelerating the recruitment of talents including key technical personnel in emerging business segments and senior executive talents with professional working backgrounds and extensive experience in overseas pharmaceutical companies to reinforce our CDMO capabilities in new modalities. In addition, we accelerated the construction of multiple production capacity expansion projects, including but not limited to the peptide commercial production, achieving a commercialized solid-phase synthesis capacity exceeding 45,000L to meet the growing demand for peptide production, prioritized the development of the exclusive production workshop for multiple pilot-to-commercialization production lines for oligonucleotide, completed Phase I commercial production capacity expansion in biological macromolecule CDMO business. As at 31 December 2025, we had multiple R&D centres, manufacturing sites, production facilities and branches/offices across China, the United States, the United Kingdom, and other regions.

- **We have maintained a stable, visionary, experienced senior executive management team who have extensive industry and operational experience with a sophisticated corporate governance sense, supported by talented and dedicated employees.** Our Company is led by the founder, Chairperson of the Board, and CEO Dr. Hao Hong and a group of senior executives with an average of more than 20 years of profound experience in their respective fields. The management team is also very stable with multiple members joining during the early days of the Company and several others who have been at the Company for over 10 years. Combined with the diversified talent pool and employees with a global vision, advanced technical knowledge, strong execution capabilities, and a strong sense of ownership, it is likely to continue driving the Company's growth.

- **We have maintained a healthy financial position with a long-term cash runway which provides flexibility for further development and overseas expansion.** After the global offering of the Company, having been successfully dual-listed on the Main Board of the Hong Kong Stock Exchange, we have more than RMB6.3 billion cash and cash equivalents on hand. Our healthy financial position and consistently efficient capital allocation provide us with flexibility to pursue our long-term strategy, i.e. rolling out our global footprint through overseas capacity expansion, dual stock markets employee share schemes, and share buybacks, etc.

v. Potential Risk Factors and Solutions

The Company is a global industry-leading CDMO enterprise, specializing in the technological innovation and commercialization of global pharmaceutical processes. It also serves as a one-stop provider of drug development and manufacturing services for large and medium-sized pharmaceutical and biotechnology companies both domestically and internationally. Potential risks that the company may encounter include issues related to the withdrawal or large-scale recall of major innovative drugs, operational challenges during clinical project stages, life cycle turnover, lower than anticipated market sales of key innovative drugs, failure to pass ongoing review by international drug regulatory authorities, loss of essential technical personnel, environmental protection and safety in production, as well as geopolitical factors, international trade disputes and exchange rate fluctuations.

I. COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to maintaining good corporate governance standards. The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the principles and code provisions as set out in the Corporate Governance Code ("**CG Code**") contained in Appendix C1 to the Hong Kong Listing Rules. During the Reporting Period, the Board is of the opinion that the Company complied with all the code provisions in the CG Code except for code provisions C.2.1 (see the section headed "Chairperson and Chief Executive Officer**"** below) and B.2.2 of the CG Code (see the section headed "Appointment and Re-Election of Directors" below).

The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code and maintain a high standard of best practices.

II. CHAIRPERSON AND CHIEF EXECUTIVE OFFICER

Pursuant to code provision C.2.1 of the CG Code as set out in Appendix C1 to the Hong Kong Listing Rules, the roles of Chairperson and chief executive officer should be separate and should not be performed by the same individual.

The roles of Chairperson and Chief Executive Officer of the Group are held by Dr. Hao Hong, who is the founder of the Group. The Board believes that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) a decision to be made by the Board requires approval by at least a majority of the Board members and that the Board comprises three independent non-executive Directors out of nine Directors, thus the Board believes that the checks and balances on the Board are sufficient; (ii) Dr. Hao Hong and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require them (among others) to act in the best interests of the Group and make decisions for the Group accordingly; and (iii) the balance of power and authority in the operation of the Board is ensured by the experienced and high caliber individuals and professionals making up the Board, who meet regularly to discuss issues affecting the operations of the Company. Moreover, the overall strategy and other key business, financial and operational policies of the Group are made collectively after thorough discussion at both the Board and senior management levels. The Board believes that the combined role of Chairperson and Chief Executive Officer can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board. Furthermore, in view of Dr. Hao Hong's industry experience, professional background, personal profile and his crucial roles in the Company as mentioned above, and also due to his deep understanding of the Group for over 20 years, Dr. Hao Hong is the best person to identify strategic opportunities and act as the key figure of the Board. Finally, as Dr. Hao Hong is the founder of the Company, the Board believes that vesting the roles of both Chairperson and Chief Executive Officer in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning and communication with the Group.

The Group and the Board are committed to high standards of corporate governance. The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether the separation of the roles of Chairperson and Chief Executive Officer is necessary.

III. APPOINTMENT AND RE-ELECTION OF DIRECTORS

Pursuant to the Articles of Association and code provision B.2.2 of the CG Code, the Directors (including non-executive Directors and independent non-executive Directors) are appointed for a specific term of three years, subject to re-election upon expiry. Directors shall be elected or replaced at general meetings with a term of office of three years, provided that the term of office of the independent non-executive directors shall not exceed a consecutive period of six years. Every Director, including those appointed for a specific term, should be subject to retirement by rotation at least once every three years.

As disclosed in the announcement of the Company dated 2 February 2024, the term of the fourth session of the Board expired on 9 February 2024. In order to ensure the continuity and stability of the work of the Board, the election of the fifth session of the Board was postponed. Accordingly, the terms of the fourth session of the Board, each special committee under the Board and senior management of the Company were extended. During the transition period and prior to the completion of the election process, all members of the fourth session of the Board, each special committee under the Board and the senior management of the Company continued to perform their respective duties and responsibilities in accordance with applicable laws and regulations and the Articles of Association.

As disclosed in the announcement of the Company dated 6 August 2025, the second extraordinary general meeting of 2025 of the Company held on the same date elected and/or re-elected three executive Directors, two non-executive Directors and three independent non-executive Directors as members of the fifth session of the Board, together with one employee representative Director elected by the employee representative assembly on 18 July 2025, the fifth session of the Board was duly formed. The term of office of the fifth session of the Board is three years commencing from the date of approval at the second extraordinary general meeting of 2025. The establishment of each special committee under the Board and the appointment of senior management of the Company were approved at the first meeting of the fifth session of the Board. Upon the election of the fifth session of the Board, the term of the fourth session of the Board has ended.

Following the election of the fifth session of the Board on 6 August 2025, the Company has complied with code provision B.2.2 of the CG Code.

IV. MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

The Company has adopted the Model Code as set out in Appendix C3 to the Hong Kong Listing Rules. Specific enquiries have been made to all the Directors and they have confirmed that they have complied with the Model Code during the year ended 31 December 2025. The Company's employees, who are likely to be in possession of unpublished inside information of the Company, are also required to comply with the Model Code. No incident of non-compliance with the Model Code by the employees was noted by the Company during the year ended 31 December 2025.

V. PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

i. A Share Repurchase

Pursuant to the repurchase plan as approved by the Shareholders on 29 February 2024, the Company repurchased part of the A Shares with self-owned funds through centralized price bidding (the "**A Share Repurchase**") which was used to implement the employee share ownership plan or the share incentive scheme of the Company and cancellation and reduction of the registered capital. The number of repurchased A Shares used to implement the employee share ownership plan or the share incentive scheme is no more than 60% of the total number of repurchased A Shares, and the number of repurchased A Shares used for cancellation and reduction of the registered capital is not less than 40% of the total number of repurchased A Shares. Such repurchase was financed entirely with the Company's self-owned funds, ensuring that the transaction price did not surpass the stipulated maximum limit of RMB157.00 per Share (inclusive) as outlined in the repurchase plan. For more details, please refer to the relevant announcements of the Company dated 31 January 2024 and 29 February 2024, and the circular of the Company dated 6 February 2024.

In light of the 2023 annual distribution of dividends, the Company adjusted the maximum repurchase price of the A Shares to RMB155.27 per Share accordingly pursuant to the requirements of the CSRC and the Shenzhen Stock Exchange, with effective from 28 June 2024 (ex-rights and ex-dividend date). For further details, please refer to the relevant announcement of the Company dated 27 June 2024.

As at 18 February 2025, the aforementioned A Share Repurchase had been completed. The implementation period for the A Share Repurchase was from 7 March 2024 to 18 February 2025. The Company had successfully accumulatively repurchased 12,300,701 A shares, representing 3.6161% of the Company's total A Share capital, through the centralized competitive bidding process on the Shenzhen Stock Exchange in 2024. The repurchase prices ranged from a minimum of RMB71.65 to a maximum of RMB102.00 per Share, utilizing a total of RMB999,644,601.56 in funds (excluding commissions and additional fees). The operation was conducted in full compliance with applicable laws and regulations, aligning with the predetermined repurchase strategy. Among the 12,300,701 A Shares repurchased, following the review and confirmation by the Shenzhen Branch of the China Securities Depository and Clearing Co., Ltd., the cancellation of the Company's repurchased 7,122,703 A Shares was completed on 26 February 2025. For further details, please refer to the relevant announcements of the Company dated 18 February 2025 and 27 February 2025. During the Reporting Period, nil Shares were repurchased under the aforementioned A Share Repurchase.

ii. Repurchase and Cancellation of Certain Restricted A Shares Granted Under the 2020 Restricted A Share Incentive Scheme and 2025 A Share Incentive Scheme

As certain Participants of the 2020 Restricted A Share Incentive Scheme resigned, on 16 August 2024, the Board considered and approved the repurchase and cancellation of 1,680 restricted A Shares under the reserved grant of 2020 Restricted A Share Incentive Scheme at a repurchase price of RMB102.46 per A Share. All funds required for such repurchase and cancellation (i.e. RMB172,132.80) are derived from our internal funds. On 3 April 2025, the first extraordinary general meeting of 2025, the first A Shares class meeting of 2025 and the first H Shares class meeting of 2025 approved such repurchase and cancellation of

restricted A Shares. Such repurchase and cancellation of restricted A Shares did not have any material impact on the operating results or financial conditions of the Company. For further details, please refer to the relevant announcements of the Company dated 16 August 2024, 3 April 2025 and the circular of the Company dated 18 March 2025. The above repurchase and cancellation of restricted A Shares had been completed as at 26 May 2025. For further details, please refer to the relevant announcement of the Company dated 26 May 2025.

As certain Participants of the 2025 A Share Scheme resigned, on 19 December 2025, the Board considered and approved the repurchase and cancellation of 33,000 restricted A Shares under the initial grant and reserved grant of the 2025 A Share Scheme at a repurchase price of RMB36.42 per A Share and RMB53.24 per A Share, respectively. All funds required for such repurchase and cancellation (i.e. RMB1,235,500) are derived from our internal funds. Such repurchase and cancellation of restricted A Shares did not have any material impact on the operating results or financial conditions of the Company, nor did it have any material impact on the Company's 2025 annual results. For further details, please refer to the relevant announcements of the Company dated 24 January 2025, 29 September 2025, and 19 December 2025 and the circular of the Company dated 18 March 2025. The above repurchase and cancellation of restricted A Shares had not been completed as at the date of this announcement. For further details, please refer to the circular of the Company dated 26 March 2026.

Save as disclosed above, during the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares). As at 31 December 2025, the Company held 1,151,300 Shares of A Shares of treasury Shares which will be used to implement the employee share ownership plans or share incentive schemes of the Company and cancellation and reduction of the registered capital.

VI. USE OF NET PROCEEDS FROM THE ISSUANCE OF SECURITIES

i. Use of Net Proceeds from the Global Offering

The net proceeds from the Global Offering (after deducting the underwriting fees and related listing expenses) (the "**Global Offering Proceeds**") amounted to approximately HKD7,318.07 million [(1)], and the balance of unutilized Global Offering Proceeds of approximately HKD992.87 million as at 31 December 2025.

The Global Offering Proceeds have been and will be utilized in accordance with the purposes set out in the Prospectus, except for the changes the Company made to the use of proceeds for several projects from time to time from 2022 to 2025. During the Reporting Period, in light of market conditions and the Company's business needs, the Company proposed to make changes in part of the use of the Proceeds in July 2025, which were later approved by Shareholders in August 2025 (the "**Changes**"). The table below sets out the planned applications of the Global Offering Proceeds and actual usage up to 31 December 2025:

Use of Global Offering Proceeds	Proportion (before the Changes)	Proportion (after the Changes)	Allocation of Global Offering Proceeds (before the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (before the Changes) *(RMB million)*	Unutilized amount (as at 1 January 2025) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(RMB million)*	Utilized amount during the Reporting Period *(HKD million)*	Utilized amount (up to 31 December 2025) *(HKD million)*	Unutilized amount (as at 31 December 2025) *(HKD million)*	Expected timeline for utilizing the remaining allocate Global Offering Proceeds
To further enhance the manufacturing capacity and capabilities of our small molecule CDMO solutions	20%	18%	1,463.61	1,195.82	599.43	1,317.25	1,076.24	376.03	1,240.21	77.04	
– To construct comprehensive small molecule R&D and manufacturing site and to purchase relevant equipment and machinery (the "**Comprehensive Small Molecule Construction Project**")	15%	13%	1,097.71	896.86	599.43	951.35	777.28	376.03	874.31	77.04	In or before December 2028
– To upgrade the equipment and machinery and expand the capacity of our existing manufacturing sites in Tianjin and Dunhua	5%	5%	365.90	298.96	–	365.90	298.96	–	365.90	–	N/A
To strengthen our Emerging Services and expand our service offerings	35%	37%	2,561.32	2,092.68	34.03	2,707.68	2,212.26	88.80	2,616.09	91.59	
– To construct a R&D and manufacturing facility for oligonucleotides and polypeptides in Tianjin and invest in R&D and manufacturing facilities for recombinant DNA products (including mAb) and ADC	20%	20%	1,463.61	1,195.82	–	1,463.61	1,195.82	–	1,463.61	–	N/A

Use of Global Offering Proceeds	Proportion (before the Changes)	Proportion (after the Changes)	Allocation of Global Offering Proceeds (before the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (before the Changes) *(RMB million)*	Unutilized amount (as at 1 January 2025) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(RMB million)*	Utilized amount during the Reporting Period *(HKD million)*	Utilized amount (up to 31 December 2025) *(HKD million)*	Unutilized amount (as at 31 December 2025) *(HKD million)*	Expected timeline for utilizing the remaining allocate Global Offering Proceeds
– To improve our capabilities related to our biosynthesis solutions and drug products solutions	10%	10%	731.81	597.91	–	731.81	597.91	–	731.81	–	N/A
– To improve our capabilities related to our biosynthesis solutions and drug products solutions and construct a R&D and manufacturing facility in Tianjin for oligonucleotides and polypeptides (the "**New Business Capabilities Construction Project**")	5%	7%	365.90	298.95	34.03	512.26	418.53	88.80	420.67	91.59	In or before December 2028
To invest in R&D initiatives and maintain our technology leadership	20%	20%	1,463.61	1,195.82	–	1,463.61	1,195.82	–	1,463.61	–	
– To upgrade our flow and continuous technology platform	10%	10%	731.81	597.91	–	731.81	597.91	–	731.81	–	N/A
– To fund the R&D initiatives led by our Center of Biosynthesis Technology (CBST)	10%	10%	731.80	597.91	–	731.80	597.91	–	731.80	–	N/A

Use of Global Offering Proceeds	Proportion (before the Changes)	Proportion (after the Changes)	Allocation of Global Offering Proceeds (before the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (before the Changes) *(RMB million)*	Unutilized amount (as at 1 January 2025) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(HKD million)*	Allocation of Global Offering Proceeds (after the Changes) *(RMB million)*	Utilized amount during the Reporting Period *(HKD million)*	Utilized amount (up to 31 December 2025) *(HKD million)*	Unutilized amount (as at 31 December 2025) *(HKD million)*	Expected timeline for utilizing the remaining allocate Global Offering Proceeds
To strategically set up foreign subsidiaries, engage in overseas investments to further expand production capacities, enhance overseas sales centers, and acquire equity interests in target companies (the "Strategic Overseas Investment and Acquisition Project")	15%	15%	1,097.71	896.86	930.27	1,097.71	896.86	106.03	273.47	824.24	In or before December 2028
For working capital and general corporate purposes	10%	10%	731.81	597.91	–	731.81	597.91	–	731.81	–	N/A
	100%	100%	7,318.06	5,979.09	1,563.73	7,318.06	5,979.09	570.86	6,325.19	992.87	

Note:

(1) The total Global Offering Proceeds included approximately HKD6,844.27 million from the Global Offering in December 2021 and HKD473.79 million from the partial exercise of over-allotment option in January 2022 as disclosed in the announcement of the Company dated 2 January 2022.

ii. Changes and Delay in the Use of Part of the Global Offering Proceeds

On 4 July 2025, in light of market conditions and the Company's business needs, the Company proposed the below changes in part of the use of the Proceeds, which were later approved by Shareholders in August 2025.

Main purposes	Proportion before the changes	Allocation of Global Offering Proceeds before the changes *(HKD million)*	Allocation of Global Offering Proceeds before the changes *(RMB million)*	Proportion after the changes	Allocation of Global Offering Proceeds after the changes *(HKD million)*	Allocation of Global Offering Proceeds after the changes *(RMB million)*	Expected timeline for utilizing the Remaining allocated Global Offering Proceeds before the changes	Expected timeline for utilizing the Remaining allocated Global Offering Proceeds after the changes
The Comprehensive Small Molecule Construction Project	15%	1,097.71	896.86	13.0%	951.35	777.28	In or before December 2025	In or before December 2028
The New Business Capabilities Construction Project	5%	365.90	298.95	7.0%	512.26	418.53	In or before December 2025	In or before December 2028
The Strategic Overseas Investment and Acquisition Project	15%	1,097.71	896.86	15%	1,097.71	896.86	In or before December 2025	In or before December 2028

Reasons for the Changes and Delay in the Use of Part of the Global Offering Proceeds

The changes in Global Offering Proceeds are aligned with the Company's future development strategy. Despite the complex and evolving international economic landscape, the fundamental trend of increasing specialization in the global pharmaceutical industry remains unchanged. Outsourcing penetration rate by big pharmaceutical companies continues to rise, and the sustained activeness of biotech companies is driving the continued expansion of the global CDMO industry. The global pharmaceutical sector is gradually recovering from its most challenging period. The emergence of GLP-1 has opened up substantial incremental market opportunities, and the ongoing momentum in drug categories such as ADCs and small nucleic acid presents new growth opportunities. In response to changes in the global pharmaceutical landscape, corresponding changes were proposed to be made to the use of the Global Offering Proceeds for the three projects above-mentioned:

The Change in relation to the Comprehensive Small Molecule Construction Project

The Company continues to improve capacity utilization efficiency through technological advancement and economies of scale. At the same time, the Company is actively expanding its overseas small molecule R&D and commercial production capacity. Accordingly, the Global Offering Proceeds for the Comprehensive Small Molecule Construction Project will be slightly reduced, and the geographical coverage of the use of the Global Offering Proceeds will be expanded from China to a global scale.

The Change in relation to the New Business Capabilities Construction Project

As the Company's emerging business enters a stage of rapid development, and in response to this trend, the Company proposes to increase investment in R&D and production facilities related to peptides, oligonucleotides, drug product, and synthetic biology solutions in response to this trend.

The Change in relation to the Strategic Overseas Investment and Acquisition Project

The Company is actively advancing its overseas strategic initiatives. In view of the longer construction cycles for overseas capacity and the time required to identify acquisition targets and close the transactions, the expected timeline for completion of use of the Global Offering Proceeds for the Strategic Overseas Investment and Acquisition Project will be moderately extended.

For more details on the changes and delay in the use of part of the Global Offering Proceeds, please refer to the announcements of the Company dated 4 July 2025 and 6 August 2025, and the circular of the Company dated 22 July 2025.

iii. Use of Net Proceeds from A Share Non-Public Offering

The Company issued 10,178,731 A Shares with an offering price of RMB227.00 per Share to designated investors in September 2020 and raised net proceeds (the "**A Share Non-Public Offering Proceeds**") of RMB2,274,960,656.06 (net of expenses related to the A Share Non-Public Offering). The following table sets out the projects funded by the A Share Non-Public Offering Proceeds and the use of the A Share Non-Public Offering Proceeds for such projects as at 31 December 2025 following the Changes in A Share Non-Public Offering Proceeds (as defined below), which was approved by Shareholders in August 2025:

No.	Implementation entity	Project name	Total investment amount *(RMB0'000)*	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (before the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (after the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Accumulated investment amount as at 31 December 2025 *(RMB0'000)*	Expected timeline to fully utilize the allocated A Share Non-Public Offering Proceeds
1.	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)	Expansion Project of One-stop Service Platform for Innovative Drugs of Asymchem Life Science (Tianjin) Co., Ltd.	68,000.00	2,204.63	2,204.63	2,204.63	N/A
2.	Shanghai Asymchem Biotechnology Co., Ltd. (上海凱萊英生物技術有限公司)	Construction Project of R&D and Production Platform for Biological Macromolecule Innovative Drugs and Preparations	62,236.45	6,551.69	6,551.69	6,551.69	N/A
3.	Asymchem Pharmacy (Jiangsu) Co., Ltd. (凱萊英藥業(江蘇)有限公司)	Biomedical R&D and Production Integration Base Project of Asymchem Pharmacy (Jiangsu) Co., Ltd. (the "**Taixing Project**")	230,938.65	60,000.00	6,632.28	6,632.28	N/A
4.	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)	Chemical Macromolecule Project of Asymchem Life Science (Tianjin) Co., Ltd.	50,000.00	40,000.00	40,000.00	40,000.00	N/A
5.	Tianjin Asymchem Biotechnology Co., Ltd. (天津凱萊英生物科技有限公司)	Key Green Technology Development and Industrialization Project of Tianjin Asymchem Biotechnology Co., Ltd.	40,000.00	13,257.10	13,257.10	13,257.10	N/A
6.	Tianjin Asymchem Biotechnology Co., Ltd. (天津凱萊英生物科技有限公司)	High-end Formulation Pilot and Industrialization Project of Tianjin Asymchem Biotechnology Co., Ltd. (the "**Formulation Pilot and Industrialization Project**")	17,195.60	10,000.00	16,000.00	12,550.99	On or before 30 June 2027

No.	Implementation entity	Project name	Total investment amount *(RMB0'000)*	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (before the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (after the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Accumulated investment amount as at 31 December 2025 *(RMB0'000)*	Expected timeline to fully utilize the allocated A Share Non-Public Offering Proceeds
7.	Asymchem Life Science (Jiangsu) Co., Ltd. (凱萊英生命科學技術(江蘇)有限公司)	Pharmaceutical R&D Center Project of Asymchem Life Science (Jiangsu) Co., Ltd. (the "**R&D Center Project**")	30,000.00	20,000.00	20,000.00	12,060.38	On or before 31 December 2028
8.	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)	Phase I Project of the Construction of Continuous Reaction Technology Service Platform of Asymchem Life Science (Tianjin) Co., Ltd. (the "**Continuous Reaction Technology Project**")	12,000.00	10,000.00	10,000.00	9,999.97	On or before 30 June 2025
9.	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)	To supplement working capital	66,057.20	66,057.20	66,057.20	66,057.20	N/A
10	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)	Chemical Macromolecule Integrated R&D and Manufacturing Project of Asymchem Life Science (Tianjin) Co., Ltd. (the "**Chemical Macromolecule Integration Project**")	50,800.00	–	47,367.72	21,432.07	On or before 31 December 2028
				228,070.62	**228,070.62**	**190,746.31**	

iv. Specific Scheme for the Changes in A Share Non-Public Offering Proceeds

To align with the Company's development strategy, and for the purpose of effectively improving the efficiency of the use of the A Share Non-Public Offering Proceeds, the Company intends to change the use of the remaining A Share Non-Public Offering Proceeds allocated to the Taixing Project, under which the remaining A Share Non-Public Offering Proceeds in the Taixing Project will be (i) reallocated to a new project — the Chemical Macromolecule Integration Project, and (ii) reallocated to the Formulation Pilot and Industrialization Project, with the expected timeline to fully utilize the allocated A Share Non-Public Offering Proceeds to be extended to 30 June 2027. In addition, the expected timeline to fully utilize the allocated A Share Non-Public Offering Proceeds for the R&D Center Project will be extended to 31 December 2028 (the **"Changes in A Share Non-Public Offering Proceeds"**). The particulars are as follows:

Project name	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (before the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Unused A Share Non-Public Offering Proceeds (before the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Amount of the Changes in A Share Non-Public Offering Proceeds *(RMB0'000)*	Investment amount proposed to be funded by the A Share Non-Public Offering Proceeds (after the Changes in A Share Non-Public Offering Proceeds) *(RMB0'000)*	Expected timeline for utilizing the remaining allocated A Share Non-Public Offering Proceeds before the Changes in A Share Non-Public Offering Proceeds	Expected timeline for utilizing the remaining allocated A Share Non-Public Offering Proceeds after the Changes in A Share Non-Public Offering
The Taixing Project	60,000.00	53,367.72	(53,367.72)	6,632.28	on or before 30 June 2026	–
The Chemical Macromolecule Integration Project	–	–	47,367.72	47,367.72	–	on or before 31 December 2028
The Formulation Pilot and Industrialization Project	10,000.00	2,394.99	6,000.00	16,000.00	on or before 30 June 2026	on or before 30 June 2027
The R&D Center Project	20,000.00	8,398.70	–	20,000.00	on or before 30 June 2026	on or before 31 December 2028

Information on the Changes in A Share Non-Public Offering Proceeds

(A) Changes in A Share Non-Public Offering Proceeds for the Taixing Project

1. Original Investment Plan and Use of Proceeds for the Taixing Project

At the inception of the Taixing Project, the Company planned to leverage its accumulated technological advantages in the field of chemical drugs to build a sustainable model characterized by low energy consumption, low emissions, and high efficiency. The objective was to enhance its integrated R&D and manufacturing capabilities for small molecule projects, support the development and commercialization of innovative drugs for indications such as diabetes, cardiovascular and cerebrovascular diseases, immune system disorders, and oncology, thereby strengthening its competitiveness in domestic and overseas markets and promoting the healthy and sustainable development of the pharmaceutical industry.

The total investment amount in the Taixing Project was RMB2,309.39 million, of which RMB600 million was originally intended to be funded by the A Share Non-Public Offering Proceeds, which included RMB214.36 million for construction works, RMB269.48 million for equipment procurement, and RMB116.16 million for installation works. The construction scope included one new manufacturing workshop, one production control center, one R&D building, and various ancillary facilities for R&D, production, and environmental protection. A total of 218 units of R&D and production equipment and 17 auxiliary systems were to be procured to support the R&D and commercial-scale production of small molecule CDMO services.

According to preliminary estimates, the Taixing Project was expected to generate a total return on investment of no less than 14.31%, with an investment payback period of less than 7.32 years (including the construction period), indicating sound economic benefits and alignment with the Company's long-term development objectives.

Before the Changes in A Share Non-Public Offering Proceeds, as at 30 June 2025, the Company had invested approximately RMB66.32 million in the Taixing Project using the A Share Non-Public Offering Proceeds, with RMB533.68 million remaining unutilized, representing progress in use of A Share Non-Public Offering Proceeds of 11.05%. The Taixing Project was determined after careful analysis based on then-prevailing market conditions, industry trends, and the Company's actual circumstances, and was consistent with the Company's development strategy at the time. After the Changes in A Share Non-Public Offering Proceeds, the allocated A Share Non-Public Offering Proceeds of approximately RMB66.32 million for the Taixing Project had been utilized as at 31 December 2025.

2. *Reasons for the Changes in A Share Non-Public Offering Proceeds for the Taixing Project*

Although the feasibility of the Taixing Project had been fully demonstrated in the early stage, considering changes in market dynamics and the Company's operating conditions, the Company believes that, as the overall efficiency of its small molecule capacity continues to improve through technologies such as continuous flow technology and with the benefit of economies of scale, the demand for capacity in the chemical macromolecule business and drug product business for new molecular types segments has become significantly more urgent. As such, the Company proposes to reallocate part of the A Share Non-Public Offering Proceeds originally intended for enhancing small molecule capabilities to these two business segments, which is expected to improve the efficiency of fund utilization and provide a solid foundation for sustaining the Company's growth. In addition, the construction of the Taixing Project will continue to be advanced in phases by the Company using other types of funds.

This change in the use of A Share Non-Public Offering Proceeds is a prudent decision made after careful consideration. The Company will continue to invest in the construction of the Taixing Project in phases using its own funds, based on the ongoing execution of small molecule project orders.

(B) The New Chemical Macromolecule Integration Project to Be Funded by the A Share Non-Public Offering Proceeds and Delay in the Expected Timeline

The Company intends to reallocate the remaining RMB473.68 million of the unused A Share Non-Public Offering Proceeds in the Taixing Project to a new project, namely the Chemical Macromolecule Integration Project of Asymchem Life Science (Tianjin) Co., Ltd.

(1) Project name: the Chemical Macromolecule Integrated R&D and Manufacturing Project of Asymchem Life Science (Tianjin) Co., Ltd.

(2) Project implementation entity: Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)

(3) Project implementation location: Western District of the Economic – Technological Development Area, Tianjin, China

(4) Project construction period: 48 months

(5) Project investment amount: RMB508.00 million, including approximately RMB486.97 million for fixed assets investment and approximately RMB11.03 million for initial working capital. The Company intends to use RMB473.68 million of the A Share Non-Public Offering Proceeds to implement this project, with the remaining balance settled through self-financing of the Company.

(6) Project construction: The project involves the construction of one quality control building and installation of 650 units/sets of R&D and manufacturing equipment for oligonucleotide, peptide, and oncology drug production in existing production workshops.

(C) The Changes in A Share Non-Public Offering Proceeds for the Formulation Pilot and Industrialization Project and Delay in the Expected Timeline

In light of the robust development of the Company's drug product business, the Company will increase the investment amount in the Formulation Pilot and Industrialization Project and extend the timeline for its completion. The particulars are as follows:

	Before the Changes in A Share Non-Public Offering Proceeds		**After the Changes in A Share Non-Public Offering Proceeds**	
Item	**Total investment amount** *(RMB0'000)*	**Committed investment amount** *(RMB0'000)*	**Total investment amount** *(RMB0'000)*	**Committed investment amount** *(RMB0'000)*
Amount of Proceeds committed to be used for the Formulation Pilot and Industrialization Project	11,000	10,000	17,195.60	16,000
Date of reaching the expected conditions for use	30 June 2026		30 June 2027	

(D) The Delay in the Expected Timeline in the Use of the A Share Non-Public Offering Proceeds for the R&D Center Project

Although the Company had conducted sufficient feasibility assessments for its proceeds-funded projects in the early stages, there remain various uncontrollable factors during the actual construction and implementation process. As at the date of this announcement, the construction works of main body of the R&D Center Project have been substantially completed. However, the procurement of certain major imported R&D equipment and custom-manufactured equipment has lagged behind the original schedule, which has to some extent affected the overall progress of this project. In addition, in line with the Company's overall development strategy, while maintaining a high utilization rate of small molecule capacity and ensuring order fulfillment, the capital expenditure for small molecule capacity has been paced at a reasonable rate, resulting in the overall progress of the R&D Center Project falling short of the original schedule and being unable to reach the expected usable condition within the expected timeline.

In view of the above, based on the actual construction progress of the R&D Center Project and the Company's development strategy, and from the perspective of long-term planning, the Company proposes, after careful consideration, to extend the timeline for the R&D Center Project to reach the expected usable condition to December 2028, without changing the project implementation entity, implementation method, use of proceeds or total investment amount.

Impact of the Changes in the Use of Part of the A Share Non-Public Offering Proceeds on the Company

The changes in the use of part of the A Share Non-Public Offering Proceeds, the establishment of a new project, the adjustment of the investment amount for certain projects, and the extension of the implementation timeline for certain projects are prudent decisions made by the Company after comprehensive assessment of the external market environment, project implementation needs, and the Company's strategic plan for future business development. These changes are conducive to improving the efficiency in the use of the A Share Non-Public Offering Proceeds, optimizing the Company's capacity layout and operational efficiency, and enhancing the Company's overall competitiveness. The changes are in line with the Company's development strategy and long-term interests, as well as the interests of all Shareholders. They do not prejudice the interests of the Company or its Shareholders, especially minority Shareholders, nor will they have any material adverse impact on the Company's operations.

For more details on the changes in the use of the A Share Non-Public Offering Proceeds and relevant new projects, please refer to the announcements of the Company dated 4 July 2025 and 6 August 2025, and the circular of the Company dated 22 July 2025.

The expected timeline for utilizing the remaining proceeds from the Global Offering and the A Share Non-Public Offering is set on the basis of the best estimation of the Company taking into account, among other factors, prevailing and future market conditions and business developments and needs, and therefore is subject to changes.

VII. CONNECTED AND CONTINUING CONNECTED TRANSACTIONS

The Group had no connected transactions or continuing connected transactions which are required to be disclosed under the Hong Kong Listing Rules during the Reporting Period.

VIII. RELATED PARTY TRANSACTIONS

During the Reporting Period, the Board of Supervisors, and after its abolition, the Audit Committee reviewed and supervised the related party transactions of the Company and concluded that the related party transactions of the Company were conducted on a fair and mutually beneficial basis, and all relevant consideration and decision-making procedures were performed, which met the actual needs of the production and operation of both parties of the related party transactions. The pricing method of the transactions was fair, and there was no prejudice to the interests of the Company and minority Shareholders.

IX. CHANGES IN INFORMATION OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVE

During the Reporting Period and up to the date of this announcement, the composition of the Board of Directors changed as follows:

Mr. Lee, Kar Chung Felix (李家聰)	Mr. Lee, Kar Chung Felix retired from the positions of an independent non-executive Director, the chairperson of the Nomination Committee and a member of the Strategy Committee. For further details, please refer to the relevant announcements of the Company dated 18 July 2025 and 6 August 2025.
Mr. Xie Weikai (謝維愷)	Following the retirement of Mr. Lee, Kar Chung Felix, Mr. Xie Weikai was appointed on 18 July 2025 to fill the vacancy of Mr. Lee, Kar Chung Felix as an independent non-executive Director. Mr. Xie Weikai was also appointed as the chairperson of the Nomination Committee and a member of the Remuneration and Examination Committee with effect from 6 August 2025. For further details, please refer to the relevant announcements of the Company dated 18 July 2025 and 6 August 2025.
Dr. Sun Xuejiao (孫雪嬌)	Dr. Sun Xuejiao was appointed as a member of the Strategy Committee and a member of the Nomination Committee with effect from 6 August 2025. For further details, please refer to the relevant announcements of the Company dated 6 August 2025.
Mr. Hong Liang (洪亮)	Mr. Hong Liang resigned as a member of the Nomination Committee with effect from 6 August 2025. For further details, please refer to the relevant announcements of the Company dated 6 August 2025.
Mr. Zhang Da (張達)	Mr. Zhang Da resigned as a member of the Remuneration and Examination Committee with effect from 6 August 2025. For further details, please refer to the relevant announcements of the Company dated 6 August 2025.

In addition, the Shareholders passed the resolutions in relation to abolition of the Board of Supervisors on 6 August 2025, pursuant to which, Ms. Zhi Xinxin, Ms. Hou Jingyi and Ms. Di Shanshan have ceased to be the Supervisors since 6 August 2025.

For further details, please refer to the relevant announcements of the Company dated 18 July 2025 and 6 August 2025 and the circular of the Company dated 22 July 2025.

Save as disclosed above, there are no other changes in the Directors', Supervisors' and chief executive's information required to be disclosed pursuant to Rule 13.51B(1) of the Hong Kong Listing Rules.

X. BOARD COMMITTEES

The Company has established four Board committees, namely the Audit Committee, the Remuneration and Examination Committee, the Nomination Committee, and the Strategy Committee.

All Board committees of the Company are established with specific written terms of reference which deal clearly with their authority and duties. The terms of reference of the Board committees are posted on the Company's website and the Hong Kong Stock Exchange's website and are available to Shareholders upon request.

Audit Committee

The Company has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Hong Kong Listing rules and the code provision D.3.3 of the CG Code and the relevant laws and regulations of the PRC. The Audit Committee is mainly responsible for reviewing and overseeing the financial reporting procedures and internal control system of the Group and provide advice and comments to the Board.

As at 31 December 2025, the Audit Committee consisted of three members, namely non-executive Director Ms. Zhang Ting, independent non-executive Directors Dr. Sun Xuejiao and Dr. Hou Xinyi with Dr. Sun Xuejiao who possesses appropriate professional qualification serving as the Chairperson of the Audit Committee.

During the year ended 31 December 2025, the Audit Committee held seven meetings to review the annual financial results and report, the interim financial results and report, the quarterly financial report, the effectiveness of risk management and internal control policies and internal audit function, the appointment of auditors and arrangements for employees to report potential misconduct.

Remuneration and Examination Committee

The Company has established the Remuneration and Examination Committee with written terms of reference in compliance with code provision E.1.2 of the CG Code and the relevant laws and regulations of the PRC. The Remuneration and Examination Committee is mainly responsible for evaluating the remuneration policies for Directors and senior management of the Group and making recommendations thereon to the Board.

As at 31 December 2025, the Remuneration and Examination Committee consisted of three members, namely independent non-executive Directors Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai, with Dr. Hou Xinyi serving as the Chairperson of the Remuneration and Examination Committee. Mr. Xie Weikai, an independent non-executive Director with appropriate professional experience, was appointed as a member of the Remuneration and Examination Committee on 6 August 2025 and Mr. Zhang Da, an executive Director, ceased to act as a member of the Remuneration and Examination Committee on the same day.

During the year ended 31 December 2025, the Remuneration and Examination Committee held a total of seven meetings to review the remuneration policies and structure of the Company, make recommendations to the Board on the remuneration packages of the Directors and senior management, review the share incentive during the Reporting Period, and etc.

Nomination Committee

The Company has established the Nomination Committee with written terms of reference in compliance with code provision B.3.1 of the CG Code and the relevant laws and regulations of the PRC. The Nomination Committee is mainly responsible for identifying, screening and recommending to the Board qualified candidates to serve as Directors and monitoring the procedures for evaluating the performance of the Board.

As at 31 December 2025, the Nomination Committee consisted of three members, namely independent non-executive Directors Dr. Sun Xuejiao, Dr. Hou Xinyi, and Mr. Xie Weikai, with Mr. Xie Weikai serving as the Chairperson of the Nomination Committee. Previously, Mr. Lee, Kar Chung Felix and Mr. Hong Liang, with appropriate professional experience, served as members of the Nomination Committee. Both of them ceased as members of the Nomination Committee on 6 August 2025, and Mr. Xie Weikai and Dr. Sun Xuejiao filled the vacancy.

When performing relevant duties, the Nomination Committee shall consider the diversity policy of the Board specified in these terms of reference. It shall be responsible for monitoring the implementation of the policy as well as reviewing and revising the policy to ensure its effectiveness.

In reviewing the size and composition of the Board, and identifying and nominating candidates for directors, the Nomination Committee shall consider relevant factors to achieve the diversity of the Board members according to the business model and specific demand of the Company. The Nomination Committee may consider the diversity of the Board members from various aspects, including but not limited to gender, age, cultural and educational background, nationality, race or ethnicity, professional expertise, skills, knowledge, and tenure of service. After considering the aforesaid relevant factors, the Nomination Committee shall make final recommendation on the appointment to the Board based on the merits of the candidates and the contribution they may bring to the Board.

During the year ended 31 December 2025, the Nomination Committee held three meetings to review the structure, size and composition of the Board and the independence of the independent non-executive Directors and Board diversity, as well as to nominate Directors and the Company's senior management for appointment.

Strategy Committee

The Company has established the Strategy Committee. The Strategy Committee is mainly responsible for reviewing and advising on long-term strategies and major investment plan of the Company.

As at 31 December 2025, the Strategy Committee consisted of three members, namely executive Directors Dr. Hao Hong and Ms. Yang Rui and independent non-executive Director Dr. Sun Xuejiao, with Dr. Hao Hong serving as the Chairperson of the Strategy Committee. Previously, Mr. Lee, Kar Chung Felix, an independent non-executive Director with appropriate professional experience, served as a member of the Strategy Committee. He ceased as a member of the Strategy Committee on 6 August 2025, and Dr. Sun Xuejiao filled the vacancy.

During the year ended 31 December 2025, the Strategy Committee held two meetings to discuss and optimize the development strategy and forward planning of the Group in 2025 and review the 2024 ESG report of the Company.

XI. AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY

In view of (i) the changes of the registered capital of the Company as a result of the repurchase and cancellation of restricted A shares of the Company, details of which were set out in the announcements of the Company dated 31 January 2024, 29 February 2024, 16 August 2024, 18 February 2025 and 27 February 2025, and (ii) the updates on requirements and interpretation of applicable PRC laws, administrative regulations and normative documents (including Guidelines on the Articles of Association of Listed Companies (2025 Revision) (《上市公司章程指引(2025年修訂)》), while taking into account the Company's actual circumstances, the Board proposed to make certain consequential amendments to the articles of association of the Company (collectively, the "**Proposed Amendments to the Articles of Association in 2025**"), among other internal rules and policies on 18 March 2025 and 18 July 2025. The Proposed Amendments to the Articles of Association in 2025 were approved at the first extraordinary general meeting of 2025, the first A Shares class meeting of 2025 and, the first H Shares class meeting of 2025 on 3 April 2025, and the second extraordinary general meeting of 2025, the third A Shares class meeting of 2025 and, the third H Shares class meeting of 2025 on 6 August 2025 as special resolutions respectively. As a result, the amended and restated articles of association of the Company became effective on 3 April 2025 and 6 August 2025 respectively. For details, please refer to the relevant announcements of the Company dated 18 March 2025, 3 April 2025, 18 July 2025, and 6 August 2025 and the circulars of the Company dated 18 March 2025 and 21 July 2025 respectively.

In view of the changes of the registered capital of the Company as a result of (i) repurchase and cancellation of part of restricted A shares granted under the 2025 A Share Scheme, and (ii) issue and allotment of new Shares to the trustee pursuant to the H Share Restricted Share Scheme, details of which were set out in the announcements of the Company dated 19 December 2025 and 13 March 2026; and Next Day Disclosure Return dated 26 January 2026, respectively, the Board proposed to make certain consequential amendments to the articles of association of the Company (collectively, the "**Proposed Amendments to the Articles of Association in 2026**"). The Proposed Amendments to the Articles of Association in 2026

are to be approved at the first extraordinary general meeting of 2026, the first A Shares class meeting of 2026 and, the first H Shares class meeting of 2026 to be held on 17 April 2026 as a special resolution. For details, please refer to the relevant announcements of the Company dated 19 December 2025, 13 March 2026 and 26 March 2026, and the circular of the Company dated 26 March 2026.

XII. ANNUAL GENERAL MEETING

The forthcoming AGM of the Company will be held on Wednesday, 10 June 2026. A notice convening the AGM will be published on the Company's website and website of the Hong Kong Stock Exchange or dispatched to the Shareholders (if requested) in accordance with the requirements of the Hong Kong Listing Rules in due course.

Corporate communications will be accessible electronically on both the Company's website at www.asymchem.com and the HKEX news website at www.hkexnews.hk. Shareholders will receive Actionable Corporate Communications either via email, using the address they provided, or in printed form.

If a shareholder prefers to receive printed communications, they may send an email to asymchem.ecom@computershare.com.hk, specifying their name, address, and language preference (English or Chinese) for printed materials. Any instructions to receive future communications in printed form will remain valid for one year from the date of the shareholder's initial request.

XIII. CLOSURE OF REGISTER OF MEMBERS

In order to determine the rights of H Shareholders to attend and vote at the AGM of the Company to be held on Wednesday, 10 June 2026, the register of members of H Shares of the Company will be closed from Friday, 5 June 2026 to Wednesday, 10 June 2026 (both days inclusive), during which period no transfer of H Shares of the Company will be registered. Members whose names appear on the register of members of the Company on Wednesday, 10 June 2026 will be entitled to attend and vote at the AGM. In order to be eligible for attending the AGM, all completed transfer forms accomplished by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Thursday, 4 June 2026.

XIV. PROFIT DISTRIBUTION PLAN

The Board proposed the following 2025 Profit Distribution Plan: distribute a dividend of RMB13.00 per 10 ordinary Shares (tax inclusive) (2024: RMB11.00 per 10 ordinary Shares (tax inclusive)) to the Shareholders as at the record date for determining Shareholders' entitlements to the 2025 Profit Distribution Plan. Based on a total of 360,874,970 Shares in issue as at 30 March 2026 and excluding 1,151,300 Shares repurchased by means of centralized price bidding, the total amount of the proposed final dividend is approximately RMB467,640,771.00 (tax inclusive) (2024: RMB395,029,822.00 (tax inclusive)[1]).

The 2025 Profit Distribution Plan is subject to the approval of the Shareholders at the AGM and the above profit distribution is expected to be paid to the eligible Shareholders on or before 24 July 2026.

1 Represents the actual final dividend for the year ended 31 December 2024 paid to the Shareholders. The total amount of the proposed final dividend for the year ended 31 December 2024 was approximately RMB390,367,340.00 (tax inclusive) as set out in the Company's annual results announcement for the year ended 31 December 2024.

Information on the closure period of the register of members of the Company in relation to the proposed 2025 Profit Distribution Plan and the record date for determining entitlements to the 2025 Profit Distribution Plan will be announced in due course.

The Board is not aware of any Shareholder who has waived or agreed to waive any dividends.

XV. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

As certain Participants of the 2025 A Share Scheme resigned, on 13 March 2026, the Board considered and approved the repurchase and cancellation of 61,000 restricted A Shares restricted A Shares granted but not yet unlocked under the initial grant and the reserved grant of the 2025 A Share Scheme, at a repurchase price of RMB36.42 per A Share and RMB53.24 per A Share, respectively. All funds required for such repurchase and cancellation (i.e. RMB2,305,720) are derived from the internal funds of the Company. For further details, please refer to the relevant announcement of the Company dated 13 March 2026. The above repurchase and cancellation of restricted A Shares had not been completed as at the date of this announcement. For further details, please refer to the circular of the Company dated 26 March 2026.

In view of the changes of the registered capital of the Company as a result of (i) repurchase and cancellation of part of restricted A shares granted under the 2025 A Share Scheme, and (ii) issue and allotment of new Shares to the trustee pursuant to the H Share Restricted Share Scheme, the Board proposed the Proposed Amendments to the Articles of Association in 2026. For details, please see the disclosure in the section headed "XI. Amendments to the Articles of Association of the Company" in this announcement.

Save as disclosed above, subsequent to 31 December 2025 and up to the date of this announcement, the Group did not have any other significant events that requires disclosure.

XVI. REVIEW OF FINANCIAL STATEMENTS BY AUDIT COMMITTEE

The Audit Committee has considered and reviewed the annual results of the Group for the year ended 31 December 2025 and the accounting principles and practices adopted by the Group and has discussed with management on issues in relation to internal control, risk management and financial reporting. The Audit Committee is of the opinion that the annual results of the Group for the year ended 31 December 2025 are in compliance with the relevant accounting standards, laws and regulations.

XVII. SCOPE OF WORK FOR ANNUAL RESULTS ANNOUNCEMENT BY AUDITOR

The figures above in respect of the Company's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended 31 December 2025 as set out in this announcement have been agreed with the Company's auditor, Ernst & Young, certified public accountants, to be consistent with the amounts set out in the Group's consolidated financial statements for the year. The work performed by Ernst & Young in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the Company's auditors in this announcement.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

Year ended 31 December 2025

	Notes	**2025**	2024
		RMB'000	*RMB'000*
REVENUE	*4*	**6,670,181**	5,804,657
Cost of sales		**(3,896,385)**	(3,422,947)
Gross profit		**2,773,796**	2,381,710
Other income and gains	*4*	**392,346**	480,715
Selling and distribution expenses		**(210,442)**	(243,391)
Administrative expenses		**(801,875)**	(861,422)
Research and development expenses		**(593,261)**	(614,490)
Impairment losses on financial and contract assets, net		**(72,614)**	(11,668)
Other expenses		**(225,696)**	(74,428)
Finance costs	*6*	**(12,751)**	(9,505)
Share of profits of associates		**36,882**	24,860
PROFIT BEFORE TAX	*5*	**1,286,385**	1,072,381
Income tax expense	*7*	**(159,743)**	(136,625)
PROFIT FOR THE YEAR		**1,126,642**	935,756
Attributable to:			
Owners of the parent		**1,132,570**	948,950
Non-controlling interests		**(5,928)**	(13,194)
		1,126,642	935,756
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic (expressed in RMB per share)	*9*	**3.16**	2.69
Diluted (expressed in RMB per share)	*9*	**3.16**	2.69

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Year ended 31 December 2025

	2025	2024
	RMB'000	*RMB'000*
PROFIT FOR THE YEAR	**1,126,642**	935,756
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(6,120)**	4,256
Other comprehensive income that cannot be reclassified to profit or loss in subsequent periods:		
Equity investments at fair value through other comprehensive income:		
Changes in fair value	**–**	(415)
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX	**(6,120)**	3,841
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	**1,120,522**	939,597
Attributable to:		
Owners of the parent	**1,126,450**	952,791
Non-controlling interests	**(5,928)**	(13,194)
	1,120,522	939,597

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

31 December 2025

	Notes	**2025**	2024
		RMB'000	*RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**6,441,721**	5,939,832
Right-of-use assets		**669,608**	699,765
Goodwill		**146,183**	146,183
Other intangible assets		**25,000**	27,490
Deferred tax assets		**275,619**	248,353
Investments in associates		**573,469**	536,587
Prepayments, other receivables and other assets		**446,007**	482,409
Financial assets at fair value through profit or loss		**193,523**	157,762
Total non-current assets		**8,771,130**	8,238,381
CURRENT ASSETS			
Inventories		**1,470,882**	1,193,346
Trade and bills receivables	*10*	**1,977,465**	1,836,887
Contract assets		**83,165**	101,470
Prepayments, other receivables and other assets		**523,270**	586,795
Tax recoverable		**13,999**	1,928
Financial assets at fair value through profit or loss		**1,116,584**	1,539,809
Amounts due from a related party		**21**	532
Cash and bank balances		**6,320,950**	5,789,408
Total current assets		**11,506,336**	11,050,175
CURRENT LIABILITIES			
Trade payables	*11*	**584,388**	449,516
Other payables and accruals		**1,247,315**	1,166,097
Financial liabilities at fair value through profit or loss		**9,836**	–
Lease liabilities		**52,711**	42,225
Tax payable		**69,472**	50,177
Amounts due to related parties		**4,765**	1,330
Total current liabilities		**1,968,487**	1,709,345
NET CURRENT ASSETS		**9,537,849**	9,340,830
TOTAL ASSETS LESS CURRENT LIABILITIES		**18,308,979**	17,579,211

CONSOLIDATED STATEMENT OF FINANCIAL POSITION *(CONTINUED)*

31 December 2025

	Notes	**2025**	2024
		RMB'000	*RMB'000*
NON-CURRENT LIABILITIES			
Deferred income		**294,734**	298,622
Lease liabilities		**256,473**	282,529
Deferred tax liabilities		**111,604**	134,703
Provision		**28**	785
Total non-current liabilities		**662,839**	716,639
Net assets		**17,646,140**	16,862,572
EQUITY			
Equity attributable to owners of the parent			
Share capital	*12*	**360,561**	367,716
Treasury shares		**(838,449)**	(1,232,758)
Reserves		**18,112,987**	17,710,426
		17,635,099	16,845,384
Non-controlling interests		**11,041**	17,188
Total equity		**17,646,140**	16,862,572

NOTES TO FINANCIAL STATEMENTS

1. CORPORATE AND GROUP INFORMATION

Asymchem Laboratories (Tianjin) Co., Ltd. is a limited liability company incorporated in Tianjin, the People's Republic of China (the "**PRC**"). The registered office of the Company is located at No. 6 Dongting 3rd Street, Economic-Technological Development Area, Tianjin, the PRC.

The Group is a world-leading, technology-driven provider of one-stop Contract Development Manufacture Organization (hereinafter referred to as "**CDMO**") solutions throughout the drug development and manufacturing process. The Group provides small molecule CDMO solutions and emerging services.

The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 10 December 2021.

The directors of the Company consider the controlling shareholders of the Company are Asymchem Laboratories, Incorporated ("**ALAB**") and Dr. Hao Hong and Dr. Ye Song, who are spouses and also controlling shareholders of ALAB. Through ALAB and their direct holdings, they held and controlled 35.89% of the equity shares of the Company.

2.1 BASIS OF PREPARATION

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards, which comprise all standards and interpretations approved by the International Accounting Standards Board (the "**IASB**"), the interpretations approved by the International Accounting Standards Committee and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for derivative financial instruments, wealth management products and equity investments which have been measured at fair value. These consolidated financial statements are presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

Basis of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries (collectively referred to as the "**Group**") for the year ended 31 December 2025. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

Generally, there is a presumption that a majority of voting rights results in control. When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

(a) the contractual arrangement with the other vote holders of the investee;

(b) rights arising from other contractual arrangements; and

(c) the Group's voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, any non-controlling interest and the exchange fluctuation reserve; and recognises the fair value of any investment retained and any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.2 ISSUED BUT NOT YET EFFECTIVE IFRS ACCOUNTING STANDARDS

The Group has not applied the following new and amended IFRS Accounting Standards, that have been issued but are not yet effective, in these financial statements. The Group intends to apply these new and amended IFRS Accounting Standards, if applicable, when they become effective.

IFRS 18	*Presentation and Disclosure in Financial Statements*[2]
IFRS 19 and its amendments	*Subsidiaries without Public Accountability: Disclosures*[2]
Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*[1]
Amendments to IFRS 9 and IFRS 7	*Contracts Referencing Nature-dependent Electricity*[1]
Amendments to IFRS 10 and IAS 28	*Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*[3]
Amendments to IAS 21	*Translation to a Hyperinflationary Presentation Currency*[2]
Annual Improvements to IFRS Accounting Standards	*Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7*[1]

1 Effective for annual periods beginning on or after 1 January 2026
2 Effective for annual/reporting periods beginning on or after 1 January 2027
3 No mandatory effective date yet determined but available for adoption

3. OPERATING SEGMENT INFORMATION

Operating segments are identified on the basis of internal reporting about components of the Group that are regularly reviewed by the Group's executive committee and the Company's board of directors for the purpose of resource allocation and performance assessment.

Operating segment

During the year, there is only one operating segment as the Group's operations relate to contract development and manufacturing which focuses on innovation and commercial application of global pharmaceutical technology.

Geographical information

(a) Revenue from external customers

	2025	2024
	RMB'000	*RMB'000*
Mainland China	**1,749,302**	1,519,908
Overseas	**4,920,879**	4,284,749
Total revenue	**6,670,181**	5,804,657

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	2025	2024
	RMB'000	*RMB'000*
Mainland China	**8,034,324**	7,543,073
United States	**39,491**	54,218
United Kingdom	**228,173**	234,976
Total non-current assets	**8,301,988**	7,832,267

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

Information about a major customer

No revenue derived from a single customer, including a group of entities which are known to be under common control with that customer was exceeding 10% of the Group revenue for the year ended 31 December 2025.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers		
Transfer of goods and services	**6,663,781**	5,797,102
Others	**6,400**	7,555
Total	**6,670,181**	5,804,657

In 2025, revenue from sale of goods amounted to RMB4,962,233,000 (2024: RMB4,568,527,000).

Revenue from contracts with customers

(a) Disaggregated revenue information

	2025	2024
	RMB'000	*RMB'000*
Types of goods or services		
Small molecule CDMO business	**4,734,651**	4,570,728
Emerging services	**1,929,130**	1,226,374
Others	**6,400**	7,555
Total	**6,670,181**	5,804,657
Geographical markets		
Mainland China	**1,749,302**	1,519,908
Overseas	**4,920,879**	4,284,749
Total	**6,670,181**	5,804,657
Timing of revenue recognition		
Goods and services transferred at a point in time		
– Small molecule CDMO business	**4,601,839**	4,469,018
– Emerging services	**1,646,985**	1,003,386
– Others	**6,400**	7,555
Subtotal	**6,255,224**	5,479,959
Services transferred over time		
– Small molecule CDMO business	**132,812**	101,710
– Emerging services	**282,145**	222,988
Subtotal	**414,957**	324,698
Total	**6,670,181**	5,804,657

4. REVENUE, OTHER INCOME AND GAINS *(CONTINUED)*

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period and recognised from performance obligations satisfied in previous periods:

	2025	2024
	RMB'000	*RMB'000*
Revenue recognised that was included in contract liabilities at the beginning of the reporting period:	**269,941**	221,204
Total	**269,941**	221,204

	Notes	**2025**	2024
		RMB'000	*RMB'000*
Other income			
Government grants		**85,106**	39,289
Bank interest income		**202,967**	210,401
Foreign exchange gain		**16,186**	131,945
Others		**153**	839
Total other income		**304,412**	382,474
Gains			
Gain on wealth management products		**52,173**	59,635
Loss on disposal of a associate		**–**	(967)
Gain on financial assets at fair value through profit or loss		**35,761**	39,573
Total gains		**87,934**	98,241
Total other income and gains		**392,346**	480,715

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	Notes	**2025**	2024
		RMB'000	*RMB'000*
Cost of sales*		**3,896,385**	3,422,947
Depreciation of property, plant and equipment*		**502,374**	461,752
Depreciation of right-of-use assets*		**67,879**	55,194
Amortisation of other intangible assets*		**4,535**	9,184
Research and development costs:			
– Current year expenditure		**593,261**	614,490
Lease payments not included in the measurement of lease liabilities		**98,988**	39,450
Auditor's remuneration		**5,780**	5,900
Employee benefit expense* (excluding directors' and chief executive's remuneration):			
Wages and salaries		**1,925,961**	1,772,936
Share-based payment expense		**8,268**	15,414
Pension scheme contributions		**212,473**	195,112
Bank interest income		**(202,967)**	(210,401)
Fair value gain on financial assets at fair value through profit or loss		**(35,761)**	(39,573)
Fair value loss on financial assets at fair value through profit or loss		**13,797**	–
Loss on disposal of items of property, plant and equipment and other intangible assets		**11,602**	6,044
Gain on disposal of right-of-use assets		**–**	(72)
Impairment losses on inventories		**58,211**	47,064
Impairment losses on items of property, plant and equipment and other intangible assets		**–**	17,830
Impairment losses on financial and contract assets, net		**72,614**	11,668
Foreign exchange differences, net		**123,799**	(130,433)

* Depreciation of property, plant and equipment, depreciation of right-of-use assets, amortisation of other intangible assets and employee benefit expense for the year are mainly included in "Cost of sales" in the consolidated statement of profit or loss.

6. FINANCE COSTS

	2025	2024
	RMB'000	*RMB'000*
Interest on lease liabilities	**12,751**	9,505
Total	**12,751**	9,505

7. INCOME TAX EXPENSE

The provision for the Chinese mainland current income tax is based on a statutory rate of 25% of the assessable profits of the Group as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008, except for certain subsidiaries of the Group in the Chinese mainland, that were accredited as "High and New Technology Enterprises" and "Western Development Policy" and entitled to a preferential rate of 15% in 2025.

Taxes on profits assessable elsewhere have been calculated at the tax rates prevailing in the jurisdictions in which the Group operates. The group entities incorporated in United States were subject to the federal corporate tax at a rate of 21% for the years ended 31 December 2024 and 2025. The group entities incorporated in the United Kingdom were subject to tax at a rate of 19% for the years ended 31 December 2024 and 2025.

	2025	2024
	RMB'000	*RMB'000*
Current	**210,108**	154,246
Deferred	**(50,365)**	(17,621)
Total tax charge for the year	**159,743**	136,625

	2025	2024
	RMB'000	*RMB'000*
Profit before tax	**1,286,385**	1,072,381
Tax at the statutory tax rate (Note (a))	**321,596**	160,857
Effect of different tax rates of subsidiaries	**(139,981)**	(7,024)
Adjustments in respect of current tax of previous periods	**5,635**	2,339
Profit attributable to associates	**1,207**	1,204
Effect of tax rate changes on opening deferred income tax balances	**(15,686)**	4,210
Deductible temporary differences and tax losses not recognised	**75,915**	56,332
Impact of tax incentives and reduction including additionally deducted for qualified research and development costs	**(93,184)**	(90,996)
Expenses not deductible for tax	**1,131**	8,519
Other	**3,110**	1,184
Tax charge at the Group's effective rate	**159,743**	136,625

(a) The Group applied the statutory income tax rate of 25% in calculating the Group's income tax expense for the year ended 31 December 2025 as the Company is no longer entitled to the preferential tax rate of 15% which is applicable to High and New Technology Enterprises, due to the fact that the proportion of the Company's revenue from high and new technology industries is lower than the required threshold.

Pillar Two income taxes

The Group is within the scope of the Pillar Two model rules. The Group has applied the mandatory exception to recognising and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes, and will account for the Pillar Two income taxes as current tax when incurred. Pillar Two legislation has been enacted or substantively enacted but not yet in effect as at 31 December 2025 in certain jurisdictions in which the Group operates.

8. DIVIDENDS

	2025	2024
	RMB'000	*RMB'000*
Proposed final – RMB1.30 (2024: RMB1.10) per ordinary share	**467,641**	395,030

The proposed final dividend for the year is subject to the approval of the Company's shareholders at the forthcoming annual general meeting.

9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the year attributable to ordinary equity holders of the parent of RMB1,125,974,000 (2024: RMB946,451,000) which has been adjusted for cash dividend of restricted shares, and the weighted average number of ordinary shares of 356,576,000 (2024: 352,106,000) outstanding during the year.

The calculation of the diluted earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the year, as used in the basic earnings per share calculation, and the weighted average number of restricted ordinary shares with a contingent non-market performance condition assumed to have been released upon vesting of all dilutive potential ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	2025	2024
	RMB'000	*RMB'000*
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the diluted earnings per share calculation	**1,132,570**	948,950
Less: Cash dividends attributable to the shareholders of restricted shares expected to be unlocked in the future	**(6,596)**	(2,499)
Profit attributable to ordinary equity holders of the parent used in the basic earnings per share calculation	**1,125,974**	946,451

	Number of shares	
	2025	2024
	'000	*'000*
Shares		
Weighted average number of ordinary shares outstanding during the year used in the basic earnings per share calculation	**356,576***	352,106
Effect of dilution – weighted average number of ordinary shares:		
Restricted A shares	**519**	2
Weighted average number of ordinary shares in issue during the year used in the diluted earnings per share calculation	**357,095**	352,108

The high cash dividend distribution plan for this year and the restricted A shares have an anti-diluting effect and were ignored in the calculation of diluted earnings per share. Therefore, the diluted earnings per share and basic earnings per share are the same.

* The weighted average number of shares was after taking into account the effect of treasury shares held.

10. TRADE AND BILLS RECEIVABLES

	2025	2024
	RMB'000	*RMB'000*
Trade and bills receivables	**2,147,128**	1,939,914
Impairment	**(169,663)**	(103,027)
Total	**1,977,465**	1,836,887

The Group's trading terms with its customers are mainly on credit. The ordinary credit period is up to 30-90 days. Each customer has a maximum credit limit. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	2025	2024
	RMB'000	RMB'000
Within 1 year	**1,875,971**	1,759,490
1 to 2 years	**71,270**	74,247
2 to 3 years	**30,191**	3,150
Over 3 years	**33**	–
Total	**1,977,465**	1,836,887

The movements in the loss allowance for impairment of trade receivables are as follows:

	2025	2024
	RMB'000	*RMB'000*
At beginning of year	**103,027**	105,823
Impairment losses recognised	**68,998**	(122)
Disposal of subsidiaries	**–**	(333)
Amount written off as uncollectible	**(2,362)**	(2,341)
At end of year	**169,663**	103,027

10. TRADE AND BILLS RECEIVABLES *(CONTINUED)*

	2025			
	Carrying amount		Impairment losses	
	RMB'000	***Rate%***	***RMB'000***	***Rate%***
Provision on a separate basis	**5,186**	**0.24**	**5,186**	**100.00**
Provision according to credit risk characteristics	**2,141,942**	**99.76**	**164,477**	**7.68**
Total	**2,147,128**	**100.00**	**169,663**	**7.90**

	2024			
	Carrying amount		Impairment losses	
	RMB'000	*Rate%*	*RMB'000*	*Rate%*
Provision on a separate basis	5,185	0.27	5,185	100.00
Provision according to credit risk characteristics	1,934,729	99.73	97,842	5.06
Total	1,939,914	100.00	103,027	5.31

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e., by geographical region, product type, customer type and rating, and coverage by letters of credit or other forms of credit insurance). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions.

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

As at 31 December 2025

	Within 1 year	**Over 1 year but Within 2 years**	**Over 2 years but within 3 years**	**Over 3 years**	**Total**
Expected credit loss rate	**2.81%**	**36.64%**	**66.92%**	**100.00%**	**7.68%**
Gross carrying amount (RMB'000)	**1,930,267**	**112,489**	**91,260**	**7,926**	**2,141,942**
Expected credit losses (RMB'000)	**54,264**	**41,218**	**61,069**	**7,926**	**164,477**

As at 31 December 2024

	Within 1 year	Over 1 year but Within 2 year	Over 2 year but within 3 years	Over 3 years	Total
Expected credit loss rate	2.23%	33.75%	60.88%	100.00%	5.06%
Gross carrying amount (RMB'000)	1,799,672	112,077	8,053	14,927	1,934,729
Expected credit losses (RMB'000)	40,182	37,830	4,903	14,927	97,842

11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2025	2024
	RMB'000	*RMB'000*
Within 1 year	**426,364**	358,342
1 to 2 years	**102,330**	56,497
Over 2 years	**55,694**	34,677
Total	**584,388**	449,516

The trade payables are non-interest-bearing and have an average term of three months.

The trade payables are measured at amortised cost, and the carrying amounts are reasonably approximate to fair values.

12. SHARE CAPITAL

Shares

	2025	2024
	RMB'000	*RMB'000*
Issued and fully paid:		
360,560,720 (2024: 367,716,423) ordinary shares	**360,561**	367,716

The ordinary shares of the Company do not have a par value.

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	**Share capital** *RMB'000*
At 1 January 2024	369,471,533	369,472
Forfeiture of restricted A Shares	(2,100)	(2)
Cancellation of repurchased restricted A Shares	(1,753,010)	(1,754)
At 1 January 2025	367,716,423	367,716
Forfeiture of restricted A Shares (Note (a))	(33,000)	(33)
Cancellation of repurchased A Shares (Note (b))	(7,122,703)	(7,122)
At 31 December 2025	360,560,720	360,561

Notes:

(a) On 19 December 2025, the board of directors of the Company has considered and approved the "Proposal on the Repurchase and Cancellation of Part of the Restricted Shares under the 2025 A Share Scheme", pursuant to which a total of 33,000 restricted A Shares granted but not yet unlocked under (i) the initial grant of the 2025 A Share Scheme held by seven incentive participants who have resigned and (ii) the reserved grant of the 2025 A Share Scheme held by one incentive participant who has resigned will be repurchased and cancelled.

(b) Pursuant to the repurchase plan as approved by the Shareholders on 29 February 2024, the Company repurchased part of the A Shares with self-owned funds through centralized price bidding (the "**A Share Repurchase**") which will be used to implement the employee share ownership plan or the share incentive scheme of the Company and cancellation and reduction of the registered capital. As of 18 February 2025, the aforementioned A Share Repurchase had been completed. The implementation period for the A Share Repurchase was from 7 March 2024 to 18 February 2025. The repurchase prices ranged from a minimum of RMB71.65 to a maximum of RMB102.00 per Share, The Company had successfully accumulatively repurchased 12,300,701 A Shares. Among the 12,300,701 A Shares repurchased, following the review and confirmation by the Shenzhen Branch of the China Securities Depository and Clearing Co., Ltd., the cancellation of the Company's repurchased 7,122,703 A Shares was completed on 26 February 2025.

PUBLICATION OF THE ANNUAL RESULTS AND THE ANNUAL REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY

This results announcement is published on the Company's website (www.asymchem.com) and website of the Hong Kong Stock Exchange (www.hkexnews.hk). The 2025 annual report of the Company containing all relevant information required under the Hong Kong Listing Rules will be despatched to the Shareholders (if requested) and published on the afore-mentioned websites in due course.

DEFINITIONS AND GLOSSARIES

In this announcement, unless the context otherwise requires, the following terms have the following meanings. These terms and their definitions may not correspond to any industry standard definition and may not be directly comparable to similarly titled terms adopted by other companies operating in the same industries as the Company.

"2020 Restricted A Share Incentive Scheme"	the 2020 Restricted A Share Incentive Scheme of the Company adopted at the Shareholders' meeting held on 9 July 2020
"2022 ESOP"	the 2022 Employee Share Ownership Plan of the Company adopted at the fifth extraordinary general meeting of 2022
"2025 A Share Scheme"	the 2025 A Share Restricted Share Incentive Scheme of the Company adopted at the first extraordinary general meeting of 2025, the first A Shares class meeting and the first H Shares class meeting on 3 April 2025
"2025 Profit Distribution Plan"	profit distribution plan for the year ended 31 December 2025
"H Share Restricted Share Scheme"	the H Share Restricted Share Scheme of the Company adopted at the first extraordinary general meeting of 2025, the first A Shares class meeting and the first H Shares class meeting on 3 April 2025
"Actionable Corporate Communications"	any corporate communication that seeks instructions from the Company's shareholders on how they wish to exercise their rights or make an election as the Company's shareholders
"ADC"	antibody-drug conjugates
"AGM" or "Annual General Meeting"	the Annual General Meeting of the Company to be held on 10 June 2026
"AI"	Artificial Intelligence
"ALAB"	Asymchem Laboratories, Incorporated, a limited liability company incorporated in the United States on November 27, 1995, which is a controlling shareholder of the Company
"API"	active pharmaceutical ingredient

"Articles of Association"	the articles of association of the Company, as amended from time to time
"Asymchem Biotechnology Development"	Shanghai Asymchem Biotechnology Development Co., Ltd. (上海凱萊英生物技術發展有限公司), a limited liability company incorporated in the PRC
"AsymCore"	AsymCore Management Consulting Partnership (Limited Partnership) (凱萊同心(天津)企業管理諮詢合夥企業(有限合夥)), a limited partnership incorporated in the PRC
"Asymchem Life Science"	Asymchem Life Science (Tianjin) Co., Ltd. (凱萊英生命科學技術(天津)有限公司)
"A Share(s)"	ordinary share(s) in the share capital of our Company, with a nominal value of RMB1.00 per Share, which are listed for trading on the Shenzhen Stock Exchange and traded in Renminbi
"Audit Committee"	the audit committee of the Board
"BLA"	Biologics License Applications, a request made to the U.S. FDA for permission to introduce, or deliver for introduction, of a biological product into interstate commerce in the United States
"Board"	the board of Directors of the Company
"Board of Supervisors"	the Board of Supervisors of the Company
"CDMO"	Contract Development Manufacturing Organization, a company that mainly provides CMC, drug development and drug manufacturing services in the pharmaceutical industry
"CEO" or "Chief Executive Officer"	the chief executive officer of the Company
"CFO" or "Chief Financial Officer"	the chief financial officer of the Company
"cGMP"	current good manufacturing practice
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Hong Kong Listing Rules
"Chairperson"	the chairperson of the Board
"China" or the "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to "China" and the "PRC" do not apply to Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan

"Clin-nov Medical"	Tianjin Clin-nov Medical Technology Development Co., Ltd. (天津凱諾醫藥科技發展有限公司) (formerly known as Tianjin Asymchem Medical Technology Development Co., Ltd. (天津凱萊英醫藥科技有限公司) with the name changed in August 2020), a wholly-owned subsidiary of the Company
"CMC"	Chemistry, Manufacturing and Controls, an important and detailed section detailing the characteristics of a therapeutic and its manufacturing and quality testing process in a dossier used to support clinical studies and marketing applications
"Company," "our Company," "the Company," "Asymchem," or "Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司)"	Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司), was established under the laws of the PRC as an enterprise legal person on 8 October 1998, the A Shares of which are listed on the Shenzhen Stock Exchange and the H Shares of which are listed on the Hong Kong Stock Exchange
"Corresponding Period"	the year ended 31 December 2024
"CSRC"	China Securities Regulatory Commission
"CRO"	contract research organization
"Director(s)"	the director(s) of the Company
"ESG"	environmental, social and governance
"FVPL"	Fair value through profit or loss
"Global Offering"	the Hong Kong public offering and the international offering of the Shares
"GLP-1"	glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity
"GMP"	good manufacturing practice
"Group," "our Group," "we," "us" or "our"	our Company and its subsidiaries
"Haihe Asymchem Fund"	Tianjin Haihe Asymchem Biopharmaceutical Industry Innovation Investment Fund (Limited Partnership) (天津海河凱萊英生物醫藥產業創新投資基金(有限合夥))
"HK$" or "HKD"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong Listing Rules"	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, as amended or supplemented from time to time

"Hong Kong Stock Exchange" or "HKEx"	The Stock Exchange of Hong Kong Limited
"IND"	investigational new drug or investigational new drug application, also known as clinical trial application in China or clinical trial notification
"Jihang Tianjin"	Jihang (Tianjin) Enterprise Management Consulting Partnership (Limited Partnership) (濟航(天津)企業管理諮詢合夥企業(有限合夥))
"Listing Date"	the date, namely 10 December 2021, on which the H Shares were listed and from which dealings in the H Shares were permitted to commence on the Hong Kong Stock Exchange
"MNC"	multinational corporation
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Hong Kong Listing Rules
"NDA"	new drug application
"NMPA"	National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理局)
"Nomination Committee"	the nomination committee of the Board
"PPQ"	process performance qualification
"Prospectus"	the prospectus of the Company dated November 30, 2021
"PMDA"	Pharmaceuticals and Medical Devices Agency, Japanese agency for drug and medical device technical review
"R&D"	research and development
"Remuneration and Examination Committee"	the remuneration and examination committee of the Board
"Reporting Period"	the year ended 31 December 2025
"RMB" or "Renminbi"	the lawful currency of the PRC
"RSU"	Restricted Share Unit

"Shanghai Asymchem"	Shanghai Asymchem Biotechnology Co., Ltd. (上海凱萊英生物技術有限公司), a wholly-owned subsidiary of the Company
"Shares"	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each
"Shareholder(s)"	holder(s) of Shares(s)
"Strategy Committee"	the strategy committee of the Board
"SZSE"	the Shenzhen Stock Exchange
"Teda"	Tianjin Economic-Technological Development Area
"Tianjin Tianhao"	Tianjin Tianhao Management Consulting Partnership (Limited Partnership) (天津天浩管理諮詢合夥企業(有限合夥))
"United Kingdom" or "U.K."	the United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom (UK) or Britain, its territories, its possessions, and all areas subject to its jurisdiction
"United States" or "U.S."	the United States of America, its territories, its possessions, and all areas subject to its jurisdiction
"US$" or "USD"	United States dollars, the lawful currency of the United States
"U.S. FDA" or "FDA"	U.S. Food and Drug Administration
"Yugen Medtech"	Tianjin Yugen Medtech Co., Ltd. (天津有濟醫藥科技發展有限公司)

APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
Chairperson of the Board, Executive Director and Chief Executive Officer

Tianjin, the PRC, 30 March 2026

As at the date of this announcement, the Board of the Company comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.